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Abstract 
Pancreatic Ductal Adenocarcinoma (PDAC) is nearly always associated with mutant K-Ras. 
Nevertheless, targeting oncogenic K-Ras has so far proved ineffective in treating this form of 
cancer and pancreatic cancer cell lines can become K-Ras independent. Other forms of Ras are 
rarely mutated but wild type N-Ras and H-Ras have been shown to be present alongside 
functional K-Ras mutations and have been demonstrated to increase responsiveness to growth 
factors. Beyond this little evidence had previously been gathered on the activity or function of 
N-Ras and H-Ras in PDAC. Therefore, this thesis aimed to determine if other Ras isoforms are 
active in PDAC cell lines and what effect they may have on controlling cell division, oxidative 
metabolism, cytokine expression and the phospholipid composition of the membrane.  
The presence of active N-Ras and K-Ras was identified in three of the four human PDAC cell 
lines tested. Only active K-Ras was detected in a cell line derived from a mouse model of 
pancreatic cancer driven by heterologous expression of mutant KRAS. N-Ras was shown to be 
functioning alongside K-Ras to control the relative level of oxidative metabolism in the Suit-2 
and a faster growing variant of the Panc-1 cell lines, but K-Ras acts alone in the slow growing 
Panc-1 cell line that does not contain N-Ras. N-Ras and K-Ras were shown to have different 
effects on the levels of cytokines, although K-Ras is largely independent of N-Ras in its 
regulation of phospholipid composition. 
A novel N-Ras independent mechanism for K-Ras transcriptional control of cyclin B1 was 
demonstrated. When K-Ras is depleted cyclin B1 and cyclin A are decreased. Cyclin B1 
transcription can be rescued by inhibition of the Proteasome. A model is proposed whereby an 
unknown protein or proteins activates cyclin B1 transcription in a cell-cycle independent 
fashion and is protected from proteasomal degradation by K-Ras.  
These results suggest that mutant K-Ras can act in conjunction with wild-type N-Ras, but also 
can function independently to regulate G2 cyclins.   
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GEFs Guanine nucleotide exchange factor 
Grb2 Growth factor receptor-bound protein 2 
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IL Interleukin  
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KPC KrasLSL.G12D/+; p53R172H/+; PdxCretg/+ 
KRAS Kirsten rat sarcoma viral oncogene homolog 
K-Ras Protein produced by Kirsten rat sarcoma viral oncogene homolog 
M Mitosis 
MAPK Mitogen-activated protein kinases 
MEK Mitogen-activated protein kinase/Erk kinase 
MRLC  Myosin regulatory light chain 
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Myt Myelin transcription factor 
NRAS Neuroblastoma RAS viral oncogene homolog 
N-Ras Protein produced by Neuroblastoma RAS viral oncogene homolog 
OCR Oxygen consumption rate Neuroblastoma RAS viral oncogene homolog 
PA Phosphatidic acid 
PAK1 P21 protein (Cdc42/Rac)-activated kinase 1 
PanIN Pancreatic intraepithelial neoplasia 
PBS Phosphate buffered Saline 
PBST Phosphate buffered Saline with tween 
PC Phosphatidylcholine 
PCho Phosphocholine 
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PE Phosphatidylethanolamine 
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Smad 
Mothers against decapentaplegic protein 
SOP Standard operating procedure 
Sos Son of sevenless protein 
TP53 
Tumour protein p53 
YAP1 
Yes associated protein 1 gene 
Zeb1 Zinc finger E-box-binding homebox 1 
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CHAPTER 1: INTRODUCTION 
 PANCREATIC CANCER  
Cancer is a common disease that can present in many different forms and it has been 
defined using six hallmarks that are traditionally thought to be the processes that require 
modification for cancer formation (Figure 1-1). (Hanahan and Weinberg, 2000) More 
recently two additional hallmarks have been proposed; reprogramming energy 
metabolism and evading immune destruction.(Hanahan and Weinberg, 2011) 
 Pancreatic cancer is one of the deadliest cancers with a high mortality rate being 
common and Pancreatic Ductal Adenocarcinoma (PDAC) is the most common form. 
Pancreatic cancer was the 14th most common cancer in the USA (48,960 estimated 
cases) in 2014 but was the 6th highest cause of cancer related death (40,560 estimated 
deaths). (Siegel et al., 2015) In 2012 pancreatic cancer was the 5th most common cause 
of cancer related death in the UK with 8662 deaths. (UK, 2014)  Patients diagnosed 
with pancreatic cancer have a median survival of just 6 months (Vincent et al., 2011) 
and currently chemotherapy has little effect, with surgery being the only possible 
curative intervention available. Even patients that undergo pancreatic head resection 
only have a 10-25% chance of 5 year survival. (Distler et al., 2013; Winter et al., 2006) 
Survival can be improved with addition of adjuvant therapy post-surgery, however 
some studies have reported that there was still a cohort of patients that will relapse 
following complete resection of the tumour. (Neoptolemos et al., 2009; Oettle et al., 
2007)    
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There are several different non-invasive ductal lesions that may occur before a cancer 
(PDAC) arises. The most widely accepted form of progression is via intraductal 
proliferation called Pancreatic Intraepithelial Neoplasias (PanINs). (Hruban et al., 2001) 
PanINs are usually microscopic lesions that occur in the pancreatic ducts and can be 
classified into three differing grades of severity based on their atypical 
structures.(Hruban et al., 2004) In addition to PDAC, other forms of pancreatic disease 
exist and these can also have K-Ras mutations present. It is still unclear why the 
pancreas seems so exquisitely prone to this particular mutation or whether this has 
effects related specifically to pancreatic transformation.  Intraductal Papillary Mucinous 
Neoplasms (IPMN) are a precursor to a non PDAC malignancy that, has also been 
shown to have mutant K-Ras present in 46% of cases.(Amato et al., 2014)  
 
: Diagram of the original six hallmarks of cancer (adapted from 
Hanahan, et al.(Hanahan and Weinberg, 2011)) 
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 K-RAS MUTATIONS OCCUR EARLY AND THEIR IMPORTANCE IN 
PANCREATIC CANCER 
The Kirsten Ras onco-protein was first identified as being expressed from the Kirsten 
sarcoma virus. Homologues to the viral gene were found in the human genome, the first 
proving to be a pseudogene, while the 2nd is a proto-oncogene referred to as 
KRAS.(Chang et al., 1982) Mutation of the KRAS gene is typically recognised as an 
early occurrence in PanIN formation and is seen in many PDACs with estimations 
ranging from 52% (Kim et al., 2011) to 93%. (Biankin et al., 2012) Other Ras isoforms 
exist (NRAS and HRAS) but have not been investigated in any great detail because 
mutations have rarely been found (Biankin et al., 2012) in PDAC and their role has 
therefore, largely been ignored. Although, there is evidence to suggest that both N-Ras 
and H-Ras are present in pancreatic cancer cells (Omerovic et al., 2008) and that they 
can be responsible for an increase in phospho Erk levels in response to Epidermal 
Growth Factor (EGF) stimulation of MiaPaCa2 cells.(Young et al., 2013) Several other 
mutations such as in SMAD4, TP53 and CDKN2A are also common and are therefore, 
assumed to be drivers, KRAS mutation is often thought of as a key early event for 
PDAC formation. Indeed the activation of the KRAS gene under its own promoter in 
pancreatic progenitor cells has been shown to be sufficient to cause the formation of 
pancreatic cancer in the mouse. (Hingorani et al., 2003) The developmental process in 
the mouse is similar to that normally observed in humans because there are PanIN like 
lesions, which appear before cancer formation. (Hingorani et al., 2003) The pancreatic 
progenitor cells are able to form islet cells, acinar cells and ductal epithelia. Switching 
on mutant K-Ras in these progenitor cells is sufficient to cause PanIN formation later in 
the life of the mouse and these can form tumours. The rate of formation of both PanINs 
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and tumours is greatly enhanced if the mice are crossed with mice engineered to express 
mutant p53 protein (known as KPC mice). (Hingorani et al., 2003) 
When K-Ras alone is mutated in the already matured acinar (Grippo et al., 2003) or 
ductal (Brembeck et al., 2003) cells, PanIN formation and subsequently cancer are not 
observed. The mutant K-Ras expressed under its own promoter that leads to PanIN has 
a stop codon that prevents production of the protein until it is looped out following Cre 
recombinase expression. The Cre is controlled by an acinar specific elastase promoter 
ensuring pancreas specific expression of the mutant protein and hence pancreatic 
tumours.(Hingorani et al., 2003) This only can occur however, if K-Ras is expressed 
during development or following cerulein induced pancreatitis if the cells have already 
differentiated (adult mice). (Guerra et al., 2007) This demonstrates the possibility that 
not only is the activation of oncogenic K-Ras required when cells have differentiated, 
but that they also require further non-genetic events such as tissue damage, or an 
inflammatory response to induce the formation of cancer.  
Loss of mutant K-Ras after the formation of the tumour in mice has been demonstrated 
to result in rapid regression of the tumour (4-5 weeks) due to apoptosis.(Viale et al., 
2014) However these tumours would rapidly reappear when oncogenic K-Ras was 
restored. They could also sporadically reoccur 4-5 months later when oncogenic K-Ras 
remained switched off. (Viale et al., 2014)  When examined further Viale A et al noted 
the presence of a subpopulation of surviving cells (SC) that were repopulating the 
tumour. When isolated and transplanted into mice, these surviving cells had a greater 
potential to form a tumour than the K-Ras dependent cells. Ablation of K-Ras signalling 
by pharmacological inhibition of MEK and PI3K pathways, similarly reduced tumour 
formation with recurrence occurring. (Viale et al., 2014) The SC demonstrated similar 
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characteristics to those produced by loss of the oncogene were observed when MEK and 
PI3K pathways were inhibited. (Viale et al., 2014) Therefore, it is suggested that in the 
heterozygous mouse tumours different subpopulations of cells exist with differing levels 
of addiction to K-Ras and some of these populations may in fact require K-Ras for 
survival. Furthermore, mutations such as the ones found in YAP1 are beginning to be 
identified as possible compensatory mutations that can negate the loss of K-Ras and 
therefore overcome K-Ras addiction. (Kapoor et al., 2014; Shao et al., 2014)  
This phenomenon of K-Ras addiction has also been observed in human cell lines, 
(Singh et al., 2009) where some cells have been shown to be addicted and therefore 
would undergo apoptosis when K-Ras is depleted.  However other cell lines that are 
defined as independent, would not undergo apoptosis although their proliferation may 
be restricted. (Singh et al., 2009) This addiction appears to be related to Epithelial- 
Mesenchymal Transformation (EMT) as cells with a more epithelial phenotype tended 
to have a greater addiction to K-Ras, than cells that presented a more mesenchymal 
phenotype. (Singh et al., 2009) Additionally treatment of K-Ras dependent lung cancer 
cell line H358 with transforming growth factor β1 to make them undergo EMT 
(measured by a loss of E-cadherin) resulted in decreased K-Ras addiction. Conversely 
depletion of Zeb1 in Panc-1 cells (K-Ras independent) resulted in a more epithelial 
phenotype and causes an increase in K-Ras addiction. (Singh et al., 2009) Gene 
expression patterns of cell lines that were addicted or independent of K-Ras were then 
used to create an expression profile to predict if other cell lines will be addicted to K-
Ras. The understanding of K-Ras addiction could have important clinical significance 
because as of yet, targeting K-Ras in the clinic has not proved successful. (Macdonald 
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et al., 2005) The existence of subpopulations of tumour cells that survive loss of K-Ras 
could be potentially responsible. 
 STRUCTURE AND FUNCTION OF RAS ISOFORMS 
 K-RAS AS A MOLECULAR SWITCH 
Ras isoforms can fine tune signals to many different downstream pathways, and K-Ras 
in pancreatic cancer has been shown to be involved in controlling multiple cellular 
functions such as; apoptosis, differentiation, migration and proliferation. (Spaargaren et 
al., 1995) K-Ras in its normal form is a GTPase that acts as a molecular switch. It is 
active when Guanosine 5’ Triphosphate (GTP) is bound in the binding pocket and 
inactive when Guanosine 5’ Diphosphate (GDP) is bound. Although K-Ras is a binary 
switch it has a gradient like response to activating signalling molecules. (di Magliano 
and Logsdon, 2013) The binding of GTP to Ras molecules is regulated by guanine 
nucleotide exchange factors (GEFs), which promote the binding of GTP by 
destabilising the nucleotide binding cleft. This destabilisation results in GDP leaving the 
binding site leaving it available for GTP binding.(Vetter and Wittinghofer, 2001)   
K-Ras alone has a limited ability to hydrolyse GTP to GDP. However, this ability can 
be increased by interactions with specific GTPase activating proteins (GAPs). (Cherfils 
and Chardin, 1999; di Magliano and Logsdon, 2013) Specific point mutations in KRAS 
result in K-Ras being unable to effectively interact with GAPs, which in turn hinders the 
conversion of GTP to GDP. (Scheffzek et al., 1997) Failure of K-Ras to return to the 
inactive state may result in inappropriate signalling, which in turn will cause 
downstream pathways to be incorrectly activated/deactivated. GTP binding to K-Ras is 
not sufficient to measure effect of K-Ras on downstream targets as subcellular 
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localisation is also important; active K-Ras is bound to the cytoplasmic membrane. 
(Campbell et al., 2006) Additionally, evaluation of the mutant KRAS gene as a 
biomarker, showed that numerous healthy individuals had mutant K-Ras containing 
cells: including in the lung, pancreas (Lu et al., 2002; Parsons and Meng, 2009; Yan et 
al., 2005) and colon. (Lu et al., 2002) An explanation for this is that as we age 
mutations are being acquired; including K-Ras mutations (Lu et al., 2002; Parsons and 
Meng, 2009; Yakubovskaya et al., 1995; Yan et al., 2005) but these do not leave the 
protein constitutively active. (Huang et al., 2014)  This was shown using a mouse model 
that had a KRAS mutant version inserted at physiological levels (one of the two copies 
was mutant) in pancreas cells. The model demonstrated that only 2% of total K-Ras was 
active in the model. (Huang et al., 2014) If KRAS mutation alone was sufficient to cause 
K-Ras protein to be constitutively active, then approximately 50% of total K-Ras 
protein would be in the active form. Oncogenic K-Ras on its own cannot generate 
enough K-Ras activity, because the mutation results only in an inefficient return to the 
inactive GDP bound state, rather than an increase in activation. (Pylayeva-Gupta et al., 
2011) The delay in inactivation will contribute to tumorigenesis because it will allow 
more time for other signals (resulting from other genetic or epigenetic changes) to act: 
maintaining an active K-Ras signal. (di Magliano and Logsdon, 2013)  
 PROMOTERS OF K-RAS ACTIVITY 
Epidermal Growth Factor Receptor (EGFR) has been shown to be involved in the 
progression of PDAC from its pre-neoplastic lesions. (Navas et al., 2012) This is in 
contrast to several other types of cancer where K-Ras mutations circumvent the need for 
EGFR. (Karapetis et al., 2008; Shigematsu et al., 2005) Activity of Erk and Akt (parts 
of the MAPK and PI3K pathways) increase when the cell is stimulated with EGF, 
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showing that mutant K-Ras alone is not adequate to activate downstream signalling 
pathways to the point of saturation. This is because despite K-Ras being constitutively 
active, EGF is still able to increase the levels of these downstream pathways. (Young et 
al., 2013) This perhaps indicates a role for wild-type Ras isoforms even in the presence 
of a mutant form. K-Ras appears to be able to make cells less sensitive to EGF 
signalling, as its loss results in an increase in the sensitivity to EGF. (Young et al., 
2013) MAPK, which is activated by K-Ras, can negatively regulate EGF and its loss 
results in greater EGF sensitivity. One method by which K-Ras decreases EGFR 
sensitivity is via MAPK. (Young et al., 2013) Chemical inhibition of MEK prevents the 
phosphorylation of EGFR at residue p.T669. The inhibition of K-Ras is less efficient at 
preventing the phosphorylation than the chemical inhibition of MEK, but it does appear 
to increase EGFR signalling. (Young et al., 2013)  Thus, other mechanisms of 
interaction between K-Ras and EGFR must exist. Ablation of EGFR prevents cerulean 
induced pancreatic fibrosis in K-Ras mutant mice. (Ardito et al., 2012) The loss of 
Adam17 was also protective. The loss of Adam17 and EGFR results in a decrease in the 
overall levels of total and active Ras. This suggests that EGFR is able to increase the 
levels of active K-Ras above the threshold early in cancer development, which allows 
for formation of the cancer cell. (Ardito et al., 2012; Huang et al., 2014) The mutation 
of TP53 relieves the need for EGFR activation. (Navas et al., 2012) In mouse models 
where TP53 is mutated, EGFR inhibition is not an effective treatment, although it is still 
an effective preventative measure, by reducing the formation of tumours. (Ardito et al., 
2012) Therefore, it is likely that EGFR is required for the initiation of tumour formation 
and its inhibition would be a good preventive strategy.  
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 DOWNSTREAM TARGETS OF K-RAS 
K-Ras is known to be the mediator of signals for multiple different signalling pathways. 
(Figure 1-2) Mutation of KRAS has profound effects on: cell proliferation; survival; 
migration (di Magliano and Logsdon, 2013) and respiration. (Ying et al., 2012) The lack 
of efficient regimen targeting K-Ras directly has led to downstream targets becoming 
prime candidates for treatment. 
 
: K-Ras signalling pathways. K-Ras is involved in the modulation of 
several different signalling pathways therefore, K-Ras is involved in many 
different cellular functions. Shown are some of the pathways that K-Ras is known 
to function through.  
 
  ROBERT FERGUSON 
 
 28  
 
 MEK/ERK MEDIATED SIGNALLING 
The MEK/Erk signalling pathway allows extracellular signals to modify the 
transcription of various genes, or change the phosphorylation status of several key 
apoptotic proteins (McCubrey et al., 2007). (Figure 1-3) This allows the cells under 
normal conditions to adapt to their environment. Ras is required to be in the active form 
before it is able to bind to Raf. This typically occurs when growth factors, mitogens or 
cytokines bind to their receptor and activate the coupling complex Shc/Grb2/Sos. 
(McCubrey et al., 2007) The resultant complex will then promote the exchange of GDP 
for GTP on inactive Ras molecules, therefore activating them and allowing Ras to 
gather Raf at the membrane. (Yan et al., 1998) In addition to localisation to the 
membrane, several other events have to occur in order to activate Raf these are: 
dimerization of Raf, (Luo et al., 1996), loss of interaction with the Raf kinase inhibitory 
protein (RKIP), (Dhillon et al., 2002; Yeung et al., 1999), the association with several 
scaffolding complexes (Chang et al., 2003; Lee and McCubrey, 2002), and 
phosphorylation or dephosphorylation of specific Raf domains. (Fabian et al., 1993) 
Once activated, Raf proteins will activate MEK1 and MEK2 by directly 
phosphorylating them. (Coles and Shaw, 2002; Ramos, 2008) MEK is only fully 
activated after it has been phosphorylated by Raf and PAK1. (Frost et al., 1997; Frost et 
al., 1996) MEK1 and MEK2 are very specific and have no other known targets than the 
Erk proteins. (Neuzillet et al., 2014) MEKs will bind to Erks when they are inactive and 
keep them localised to the cytoplasm. (Fukuda et al., 1997) Once MEKs are activated 
they will phosphorylate Erks which results in their activation, and once active, MEKs 
release Erks allowing them to dimerise and translocate to the nucleus. (Ramos, 2008) 
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Active Erks in the nucleus or cytoplasm will bind to multiple different transcription 
factors, phosphatases and cytoskeletal proteins.  
Erks are able to directly control the activity of transcription factors by phosphorylating 
them. This phosphorylation can be regulatory in several different ways. It can change 
their activity, binding affinity to DNA, subcellular localisation or the levels of protein 
present. (Yang et al., 2013) Activated Erk1 is able to phosphorylate Smad2 which 
stabilises the protein and increases the levels in the cell. Funaba et al demonstrates that 
this phosphorylation of Smad2 is required for maximal transcription of Smad2-
dependant genes. The increase in Smad2 transcriptional activity is due to the protein 
being more stable, and therefore, being able to form a greater number of transcriptional 
activator complexes with Smad4. (Funaba et al., 2002) 
The transcription factor Myc which targets include cyclin D, cyclin E, and E2F 
(Bretones et al., 2014) is also stabilised by phosphorylation by the MAPK pathway. Erk 
activation results in the phosphorylation of Ser 62 of the Myc protein stabilising it. 
(Sears et al., 2000) Another phosphorylation site at Thr 58 is targeted by glycogen 
synthase kinase (GSK-3) but this phosphorylation occurs after Ser62 has been 
phosphorylated. Thr 58 phosphorylation unlike Ser 62 results in the degradation of 
Myc. GSK-3 phosphorylation of this site can be prevented by PI3K signalling. (Sears et 
al., 2000) Therefore, two different downstream pathways of Ras are involved in the 
upregulation of the Myc transcription factor.  K-Ras via MAPK signalling is also able to 
upregulate the transcription of cyclin D1 by stimulating the expression of activator 
protein 1 (AP-1) transcription factors. AP-1 can bind to the AP-1 binding site in the 
promoter region of cyclin D and stimulate its transcription. (Klein and Assoian, 2008).  
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Ras signalling via Erk is complex with feedback loops that can downregulate or 
upregulate Erk signalling. This is vital to ensure correct control of cell division and 
metabolism. (Owens and Keyse, 2007; Ramos, 2008) Erk can downregulate MEK 
directly by phosphorylating it, preventing MEK from being able to interact with PAK1. 
Thus removing PAK1’s ability to enhance MEK’s activation of Erk. (Slack-Davis et al., 
2003) Phosphorylation of Raf at multiple sites by Erk prevents it being able to interact 
with Ras. (Dougherty et al., 2005) The inability of Raf to interact with Ras stimulates 
the dephosphorylation of the Ras bound GTP to GDP. (Ramos, 2008)  
The Erk mediated phosphorylation of Sos was one of the first feedback loops in the 
Ras/Raf/MEK/Erk pathway to be discovered. (Corbalan-Garcia et al., 1996) Sos is a 
guanine nucleotide exchange factor (GEF) that interacts with Ras to activate it. The 
phosphorylation of Sos prevents its localisation to the plasma membrane where it 
normally interacts with Ras. The phosphorylation of Sos is not by Erk directly, but is 
mediated via RSK2 (Douville and Downward, 1997) which is activated by Erk directly 
in the cytoplasm. (Hauge and Frodin, 2006)  
In the cytoplasm, Erk phosphorylates DUSP6 targeting it for degradation via the 
proteasome. (Marchetti et al., 2005) This acts as a positive feedback loop as 
phosphorylation of DUSP6 prevents it from being able to dephosphorylate Erk, leaving 
Erk active. (Muda et al., 1996) In contrast in the nucleus, phosphorylation of DUSP1 by 
Erk stabilises it, creating a negative feedback loop. (Brondello et al., 1997; Brondello et 
al., 1999) The regulation of DUSPs by Erk therefore will vary depending on where in 
the cell the phosphorylation is occurring. Localisation of Erk within the cell is an 
important aspect of cell signalling. Phosphorylation of Erk by MEK followed by its 
release (MEK binds to inactive Erk) allows for Erk dimerization, and is a key 
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component of the rapid translocation of Erk to the nucleus. (Cobb and Goldsmith, 2000; 
Khokhlatchev et al., 1998) The phosphorylation of Erk results in a confirmation change, 
which then results in the Dimer Interface of the protein being exposed, allowing two 
Erk molecules to form a dimer. (Canagarajah et al., 1997) The import of the active 
dimerised phosphorylated Erk to the nucleus predominately requires energy and 
cytosolic factors. (Ranganathan et al., 2006) This is in contrast to the singular non-
phosphorylated inactive Erk, which does not require any energy or carrier proteins to 
enter the nucleus. (Ranganathan et al., 2006) MEK, as mentioned previously when 
inactive, will bind to Erk that has not been activated, this will keep it localised in the 
cytoplasm. (Fukuda et al., 1997) In addition MEK has been shown to be involved in the 
nuclear export of monomers of inactive Erk. (Adachi et al., 2000) The dimerisation of 
Erk has been suggested to hide the MEK binding site, further facilitating the localisation 
of Erk to the nucleus.(Cobb and Goldsmith, 2000)  
In addition to MEK there are other proteins that interact with Erk to regulate its location 
throughout the cell. (Ramos, 2008) One other example is Sef, which can bind to Erk and 
blocks its nuclear localisation, but it does not prevent its phosphorylating activities in 
the cytoplasm. (Torii et al., 2004) It does this by binding to active MEK and preventing 
active Erk from dissociating from MEK. (Torii et al., 2004) The Sef/pMEK complex is 
located to the Golgi apparatus or the membrane ruffles, (Ramos, 2008) suggesting that 
Sef is involved in locating active Erk signalling to these parts of the cell. In contrast 
Mxi2 has been identified as a protein that binds directly to Erk, promoting its 
accumulation in the nucleus, (Casar et al., 2007) and prolonging its activation while 
having no effect on Erk’s cytoplasmic function. (Sanz-Moreno et al., 2003)  
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Non phosphorylating inhibitors of Erk/MAPK signalling also exist. RKIP binds to Raf 
and MEK, inhibiting their ability to interact with each other (Yeung et al., 1999) and a 
loss of RKIP results in increased Erk signalling. (Ramos, 2008) Several metastatic 
cancers have been shown to downregulate RKIP (Ramos, 2008) and its over expression 
reduces the invasive potential of cancer cells. (Al-Mulla et al., 2013; Das et al., 2012; 
Schuierer et al., 2004) RKIP is believed to play an important role in suppressing 
metastasis. (Keller, 2004)  
Therefore it is clear that regulation of the Raf/MEK/Erk signalling pathway is complex, 
and that specific signals are activated to regulate the intensity and duration of Erk 
signalling, depending on the requirements of the cell at that time. This is important 
because Erk has so many different possible targets that precise regulation of the 
pathway is required to ensure the correct targets are activated at the correct time. Loss 
of regulation (by K-Ras mutation for example) of this pathway can result in increasing 
the tumorigenic potential of a cell. 
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: Diagram of the Raf/MEK/Erk signalling pathway. Raf can be phosphorylated by Ras and other kinases. This phosphorylation of Raf 
activates it and promotes phosphorylation of its downstream targets, and ultimately the activation of multiple downstream genes. 
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 PI3K MEDIATED SIGNALLING 
The PI3K/Akt signalling pathway is also downstream of Ras and there are several areas 
of cross talk between the Raf/MEK/Erk and PI3K/Akt pathways. Mutation of Akt to 
express the dominant active form was shown not to be sufficient for PanIN formation in 
mice, but did lead to the formation of ductal structures and activation of progenitor cell 
associated genes. (Elghazi et al., 2009) Expression of the mutant form of Raf when 
TP53 is mutated was sufficient to cause the development of lethal PDACs, but the 
dominant active form of PI3K was not. (Collisson et al., 2012) However, PI3K has been 
shown to be required for the initiation and maintenance of carcinogenesis in the 
pancreas. (Eser et al., 2013) It would therefore appear that PI3K is not required to 
mimic the effects of K-Ras activation during PDAC formation in mice, but MAPK 
signalling is.  
Once the tumour has formed, the requirements for signalling may be different to those 
required for the initiation of tumour formation. This was tested using pharmacological 
inhibitors. Inhibition of MEK with PD325901 causes tumour growth to be halted in 
KPC mice. Mice that were treated with this inhibitor survived longer than those without 
it, but they died shortly after the treatment was stopped. (Collins et al., 2012) Raf 
inhibitors by contrast did not prevent the growth of pancreatic cancer cell lines when 
they were treated and in fact interfered with the MEK inhibitors when the compounds 
were applied together. (di Magliano and Logsdon, 2013; Hofmann et al., 2012) The 
combined treatment of MEK inhibitors and Akt inhibitors in multiple different 
pancreatic cancer cell lines did however, have a synergistic anti-proliferative effect 
which was shown using several different inhibitors of each pathway in combination. 
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(Hofmann et al., 2012) Furthermore, the combination of these drugs in mice caused a 
regression in their tumours, but either drug alone only slowed the growth of the tumour. 
(Hofmann et al., 2012) It seems that both Akt and Erk signalling are important for the 
maintenance of tumour progression, and perhaps the cross talk between the two 
pathways can negate some of the effects of inhibiting earlier parts of the pathway.  
 RAL GTPASES 
Ras-like GTPases (Rals) were initially discovered in a screen of simian B lymphocytes 
using a conserved 7 amino acid sequence from Ras, RhoA and yeast YPT Rab protein. 
(Neel et al., 2011) The Ral A gene was shown to have 50% sequence homology with 
genes of the Ras family. The sequence for simian Ral A was used to isolate the human 
homolog along with another gene RALB. (Chardin and Tavitian, 1986) Although these 
genes share similar sequence homology (82%) they have different functional roles 
within the cell. Rals are well conserved throughout species with Caenorhabditis elegans 
and Drosophila melanogaster encoding Ral GTPases, which are similar to RalA/B. 
(Neel et al., 2011)  
Ral A and B require the binding of GTP to become active in a similar manner to Ras; as 
with Ras, GEFs are needed to promote GTP binding. The first RalGEF (RalGDS) was 
found in mice when looking for genes that shared a similar sequence to yeast RasGEFs. 
(Albright et al., 1993) RalGDS was found to have sequence homology with several of 
the active regions of RasGEFs, but they did not demonstrate activity with Ras. They 
were instead shown to be involved in the exchange of GTP for GDP in both Ral A and 
Ral B. (Neel et al., 2011) It appears that several of the Ral GEFs can also interact with 
Ras, and that Ras appears to be involved in activating them. (Ferro and Trabalzini, 
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2010) Ral therefore is another downstream effector of Ras. Ral is known to interact with 
several downstream effectors such as Ral binding protein 1 (RalBP1), which was the 
first effector discovered. (Cantor et al., 1995) Active RALs bind to the conserved Ral 
binding domain of RalBP1 and regulate its subcellular localisation, but not its activity 
or function. (Matsubara et al., 1997) RalBP1 has been demonstrated to contain two ATP 
binding sites and is involved in the transport of small molecules including anti-cancer 
drugs. (Vatsyayan et al., 2010) The inhibition of RalBP1 expression has been 
demonstrated to result in a regression in tumours of multiple different xenographs. 
(Neel et al., 2011) 
In H460 (a K-Ras mutant lung cancer cell line) survivin was shown to be degraded 
when K-Ras or RalA was depleted. Survivin is a target of the Anaphase Promoting 
Complex/cyclosome (APC/c).  Targeting RalA or K-Ras for depletion caused a greater 
decrease in survivin levels than when RalB was depleted. By contrast when another 
lung carcinoma cell line (A549) was tested it was shown to be more dependent on RalB 
to regulate the level of survivin. (Tecleab and Sebti, 2013) Depletion of RalB in this cell 
line was even more potent than K-Ras depletion. (Tecleab and Sebti, 2013) This 
degradation could not be replicated by the depletion of Raf-1 or Akt1/2, suggesting that 
the regulation of survivin levels in these lung cancer cell lines was mediated through the 
Ral pathway, rather than the more classically considered effectors of Ras signalling. 
(Tecleab and Sebti, 2013)   
 MYC 
Myc (gene MYC) is a transcription factor that is known to be involved in many 
different pathways that regulate growth, apoptosis, differentiation and proliferation of 
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cells. (Cole, 1986; Luscher and Eisenman, 1990; Prendergast, 1999) In pancreatic 
cancer the region of the chromosome containing the MYC gene has been shown to have 
an increased copy number, which has been suggested to be related to its overexpression 
in pancreatic cancer cells. (Schleger et al., 2002) Myc is activated by Ras/Raf MEK/Erk 
pathway through phosphorylation of serine 62 which stabilises the Myc protein. 
Phosphorylation of threonine 58 by GSK-β results in Myc destabilisation, but this can 
only occur after Serine 62 has been phosphorylated. (Lutterbach and Hann, 1994; Sears 
et al., 2000) Ras via PI3K/Akt can inhibit GSK-β, and therefore activation of Ras is able 
to stabilise Myc as well as prevent the destabilisation of the stable form by the 
inhibition of GSK-β activity. (Sears, 2004) When active, Myc binds to the promoter 
regions of several key components of the cell cycle such as cyclins and several cyclin 
dependent kinases. (Cdks) (Bretones et al., 2014)  It has therefore been determined to be 
involved in the cell cycle and provides a pathway by which Ras expression interacts 
with the cell cycle.   
 PHOSPHOTIDYLCHOLINE AS A LIPID MEMBRANE COMPONENT. 
Phosphatidylcholine (PC) is a vital component of lipid membrane formation and cell 
signalling. In mammalian cells PC is synthesised from choline via the Kennedy (CDP-
choline) pathway in most cell types, and is the main component of multiple 
phospholipids found in the membrane such as: phosphatidylinositol, (PI) 
phosphatidylserine, (PS) and phosphatidylethanolamine (PE) (Janardhan et al., 2006) 
(see Figure 1-4). PC is degraded via a specific phospholipase D (PLD) and both the 
creation and degradation are regulated to create PC homeostasis. Fluctuation of PC 
levels (either increased or decreased) can result in cell death. (Janardhan et al., 2006)  
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Stimulation by mitogenic growth factors or oncogenic transformation results in PLD 
mediated hydrolysis of PC into choline and phosphatidic acid (PA). This choline along 
with choline that has been acquired from outside sources enters the Kennedy pathway 
(Figure 1-4). (Hernandez-Alcoceba et al., 1999) Choline is then converted through 
several intermediates to PC, which can then be used as a building block for several 
membrane phospholipids. Phosphocholine (PCho) is one of the intermediates generated 
through the Kennedy pathway, and its level is controlled through the activity of Choline 
Kinase (ChoK) and PLD. (Janardhan et al., 2006) PCho is stable and essential in the 
induction of DNA synthesis (Cuadrado et al., 1993) and so PCho, via the Kennedy 
pathway is thought to be an important step in the regulation of cell proliferation and 
malignant transformation. (Rodriguez-Gonzalez et al., 2003) 
Mutant Ras can enhance the activity of ChoK through the Ral-GDS and PI3K pathways. 
(Ramirez de Molina et al., 2002) The inhibition of ChoK appears to be able to be an 
effective antitumor strategy against cells transformed in this manner. (Ramirez de 
Molina et al., 2001) Raf signalling was shown not to have a significant effect on ChoK 
activity. (Ramirez de Molina et al., 2002) It has therefore been demonstrated that 
mutant Ras can affect ChoK activity. Ras may therefore be able to alter the lipid 
profiles of the membranes of transformed cells. In support of this the genesis of 
lymphoma by activation of different oncogenes (Myc and Ras) results in a change in 
lipid profile. (Eberlin et al., 2014) 
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 K-RAS AS A TARGET FOR TREATMENT  
The global presence of Ras isoforms in cellular signalling, coupled with the high 
frequency of K-Ras mutations, make it an attractive target for clinical therapies. At the 
time of writing, a successful treatment has not been developed.(Macdonald et al., 2005) 
It may be that no effective small molecule has been identified, but it may also be due to 
the ability of subpopulations of pancreatic cancer cells to survive the loss of K-Ras. The 
surviving cell (SC) population may be able to aggressively repopulate following the end 
of treatment. (Viale et al., 2014) There may even be a population that could survive 
with continued treatment because they have become independent of K-Ras. (Singh et 
al., 2009)  
A potential new treatment featuring compounds that bind specifically to p.G12C K-Ras 
mutations has been demonstrated in cell lines. Binding of these compounds inhibits the 
function of mutant K-Ras in two ways. It increases the affinity of the mutant K-Ras to 
GDP instead of GTP resulting in its inactivation, and it also diminishes the interaction 
that K-Ras can have with its downstream targets. (Ostrem et al., 2013) The specificity 
of this treatment means that it does not affect wild type K-Ras. However, this is not an 
effective treatment for other K-Ras mutants and so identification of other agents is 
required. Characterisation of pathways downstream of K-Ras (perhaps undiscovered so 
far) that are involved in cellular processes such as growth and maintenance of the 
cancer cell, will offer potential alternative targets for treatment that can be used 
independently or in combination with K-Ras inhibition. 
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: Diagram showing the synthesis of Phosphatidylcholine from PCho via the CDP-choline Kennedy pathway. Ras can modulate the 
Kennedy pathway and therefore regulate the levels of different components of the pathway. This regulation allows Ras to control the makeup of 
the lipid membrane, as well as altering signalling downstream.  
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 CELL CYCLE  
 OVERVIEW 
The cell cycle can be thought of as two separate parts: mitosis (M) where nuclear 
division occurs and interphase, which is the phase between two concurent mitoses. 
(Figure 1-5). Mitosis is divided into prophase, metaphase, anaphase, telophase, and 
cytokinesis. There are three separate parts to interphase (G1, S and G2 phases) (Figure 
1-5) . (Norbury and Nurse, 1992) Cells grow in size during G1 (hence the archaic name 
of ‘Growth’ phase) before entering S phase to replicate their DNA. Following S phase 
the cell enters G2 where it prepares for cell division that will occur in mitosis. Cells can 
also move into G0 from G1 where they are in a non dividing state. This quiescent state 
is where most normal cells reside.(Vermeulen et al., 2003)  
 
: Diagram demonstrating the phases of the cell cycle. The main cyclins 
and Cdks are shown with their most recognised point of action demonstrated, 
other cyclin-Cdk interactions (although important) are not included for simplicity. 
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 CONTROL OF THE CELL CYCLE 
As mentioned previously, the cell cycle is divided into several different phases that have 
to be completed sequentially to successfully result in the genesis of two daughter cells. 
Cyclin dependent kinase (Cdks) are responsible for the regulation of gene expression at 
the different stages of the cell cycle (Figure 1-5). This control can occur through the 
activation of transcription factors that promote the transcription of the genes of interest. 
Cyclin E/Cdk2 for example, can phosphorylate pRB (Retinoblastoma protein) which is 
inhibitory when bound to the transcription factor E2F. pRB phosphorylation dissociates 
it from E2F increasing its ability to activate transcription (Figure 1-6). (Dyson, 1998; 
Takahashi et al., 2000)  Different Cdks are found to be active in different parts of the 
cell cycle, but the levels of Cdks tend to be constant. The levels of Cdk activator 
proteins (cyclins) oscillate throughout the cell cycle and dictate the Cdks that are active 
and when. (Morgan, 2007) Activation of Cdks has to occur in a sequential manner and 
once it starts the cell will complete a full cycle. This is to prevent multiple incomplete 
firings of the cell cycle which could lead to mistakes being made in cell division and 
usually cell death.(Morgan, 2007) 
Cdks have a similar structure to other protein kinases with two lobes forming a cleft into 
which ATP fits. (De Bondt et al., 1993) There are two additional modifications 
compared to other protein kinases.   The modifications have been identified by studying 
the crystal structure of human Cdk2. They are firstly a large loop structure that blocks 
entry into the substrate binding pocket. Secondly, several of the amino acid side chains 
are not located in the standard position within the ATP binding site. (De Bondt et al., 
1993) Both of these features keep Cdks inactive when they are not bound to cyclins. 
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Cyclins are different from each other in their amino acid sequences. However, they all 
contain a conserved 100 amino acid sequence known as the cyclin box.(Brown et al., 
1995; Petri et al., 2007) Despite the differences in sequence, their tertiary structures 
always contains a region known as the cyclin fold. This region consists of two domains 
of 5 α-helices. One of these domains is made up of the cyclin box, the other is made up 
of a similar arrangement of helices although the primary structures can contain little 
homology. (Brown et al., 1995; Petri et al., 2007) This cyclin fold region is also found 
in several transcriptional regulators, which may indicate that they have evolved from a 
common ancestor protein. (Morgan, 2007)  
In addition to the binding of cyclins to the Cdk, further phosphorylation at a threonine 
residue next to the active site is required for full activation. (Morgan, 1997) Cdk-
activating kinases (CAKs) are responsible for the phosphorylation of this residue to 
complete the activation of Cdks. (Harper and Elledge, 1998; Morgan, 2007) Unlike 
most phosphorylation modifications this one appears to be irreversible but it only occurs 
in mammalian cells after the binding of cyclins. (Morgan, 2007) The CAKs appear to be 
at high levels throughout the cell cycle, therefore, it is the binding of cyclins that is the 
rate limiting step for the activation of Cdks. (Morgan, 2007) In addition to these 
activating mechanisms, phosphorylation of Tyrosine 15 and Threonine 14 of Cdks is 
inhibitory. Both of these residues are found in the roof of the ATP binding pocket and 
their phosphorylation likely interferes with the orientation of the ATP phosphates. Thus 
preventing the Cdks ability to perform its kinase function. The phosphorylation state of 
these residues is closely regulated by kinases and phosphatases. In eukaryotes, the 
dephosphorylation is mediated by members of the Cdc25 family and phosphorylation is 
carried about by Wee1 (Tyr 15) and Myt1 (Tyr 14 and 15). (Dunphy, 1994)  
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The crystal structure showing the conformational changes that occur when cyclins bind 
to Cdks, has been done initially using Cdk2 binding to cyclin A. It has been inferred to 
be similar for other cyclin/Cdk interactions. (Brown et al., 1999; De Bondt et al., 1993; 
Petri et al., 2007) The binding of different cyclins to the same Cdk demonstrates 
differing kinase activity towards the same target sequence. This suggests that some 
differences must exist in how the cyclins promote the kinase activity. (Morgan, 2007) 
Cyclin A binding interacts with both lobes of Cdk and the T-loop is moved from 
blocking the protein binding site. Additionally residues that are misaligned in the ATP 
binding pocket are now correctly aligned to allow the phosphotransfer reaction to take 
place. (Jeffrey et al., 1995; Russo et al., 1996) The binding of cyclin A results in 
conformational changes to Cdk2, allowing its substrate to bind as well as reconfiguring 
the ATP binding pocket to an active form. In addition, the binding of Cyclin A also 
provides a ridged framework, which supports Cdk2. (Jeffrey et al., 1995) 
In addition to activating Cdks some cyclins can specifically target Cdk substrates. This 
potentially could be important in ensuring that the correct downstream targets are 
activated at the same time, because different cyclins can target the same Cdk at different 
points in the cell cycle. (Miller and Cross, 2001; Roberts, 1999) An example of this is 
that Cdk1 and Cdk2 will bind to p107 when they are bound by cyclin A, but not when 
bound by cyclin B. (Morgan, 2007; Peeper et al., 1993) This mechanism provides 
greater flexibility for regulating downstream targets than if specificity was defined by 
the Cdk alone. In addition cyclins are able to locate the cyclin/Cdk complex to specific 
parts of the cell, at various points in the cell cycle to regulate their function by partition. 
(Pines and Hunter, 1991)  
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Degradation of proteins via the proteasome (proteolysis) is an important mechanism of 
regulation for the cell cycle.  It helps ensure that the cell cycle is sequential by 
degrading regulatory proteins when they are not required. Additionally, degradation of 
regulatory proteins after cell division has occurred can ensure that another round of cell 
division does not occur too quickly. Proteins that are designated to undergo proteolysis 
are tagged by multiple copies of the small protein ubiquitin tag in a multi-step process. 
(Pickart, 2001) Proteins that are tagged by ubiquitin are recognized by the proteasome 
and undergo proteolysis.  
Of particular relevance to the cell cycle there are two different large multi-subunit 
ubiquitin-protein ligases that are responsible for correctly tagging proteins to be 
destroyed. SCF (its name derived from its key components Skp1, cullin and the F-box) 
is the key ligase complex for the ubiquitination of Cdks at the G1/S transition. (Orlicky 
et al., 2003; Zheng et al., 2002) The F-box of SCF determines the target specificity of 
the complex. With several different F-boxes being interchangeable to create specific 
targeting for different subsets of proteins. For example the F-box protein Cdc4 targets 
cyclin E for degradation. (Jin et al., 2004)  
The other main complex that is important in the regulation of the degradation of cell 
cycle proteins is the Anaphase Promoting complex (APC/c). The APC/c is controlled by 
activator subunits binding which bind to the APC/c core proteins at different times 
during the cell cycle. Cdc20 and Cdh1 are two of these activators and they play a key 
role in the control of the cell cycle. Cdc20 is involved in activation of the APC/c when 
cells are transitioning from anaphase to metaphase, and promotes the segregation of 
sister chromatids and exit from mitosis.  
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Phosphorylation of core APC/c subunits by Cdks increases the binding affinity for 
Cdc20. (Harper et al., 2002; Peters, 2002) Once bound APCCdc20 targets these same 
Cdks for destruction and therefore generates a negative feedback loop on its activation. 
This destruction of Cdks via APCCdc20 is a delayed event after activation, ensuring that it 
does not occur too early in mitosis. (Morgan, 2007; Peters, 2002) The destruction of 
Cdks and their activating cyclins (A+B) results in less phosphorylation of the APC/c, 
therefore Cdc20 dissociates. Loss of Cdc20 binding to the APC/c results in its 
inactivation. This mechanism results in an inactive APC/c by the end of mitosis. 
(Harper et al., 2002; Peters, 2002)   
All cells apart from early embryonic cells do not undergo another round of cell division 
immediately and these cells will enter G1. The reactivation of the G2 Cdks and G2 
cyclins would therefore be disruptive to this plan. To maintain the cells in G1, the G2 
Cdks and cyclins activity are inhibited, their transcription downregulated, and they are 
also degraded via the proteasome. These are targeted for degradation via the APC/c, 
however in G1 the APC/c is activated by the binding of Cdh1. (Harper et al., 2002; 
Peters, 2002) Cdh1 does not bind to the APC/c when it is phosphorylated by Cdks. 
Therefore Cdh1 binds and regulates activity after the completion of mitosis when Cdc20 
has dissociated, and the Cdks that can phosphorylate the APC/c, are inactive. APCCdh1 
therefore is active through G1, keeping cyclin B and it related Cdks at low levels until 
the cell is ready to undergo another round of cell division. (Harper et al., 2002; Morgan, 
2007; Peters, 2002) The G1 cyclins (cyclin D and E) are not recognized by APCCdh1 and 
therefore the activity of the G1/S Cdks will rise as the cell approaches another round of 
cell division. (Harper et al., 2002) When the levels of the G1/S Cdks have risen they 
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phosphorylate Cdh1, dissociating it from the APC/c, thereby inactivating it and 
allowing cyclin B levels to rise again. (Harper et al., 2002) 
As previously discussed Cdk levels tend to be relatively stable (Sullivan and Morgan, 
2007) and their activation is regulated by other proteins. The combination of these 
regulatory mechanisms results in a mechanism that can control complete and accurate 
formation of daughter cells.  Cyclin D has 3 different isoforms (D1, D2, D3) with D1 
being the most commonly considered. All three D type cyclins are able to bind to Cdk4 
and Cdk6 (Figure 1-5). The binding and activation of these Cdks is required to allow the 
cells to enter G1 from G0. (Sherr, 1994) Once active Cdks will phosphorylate 
downstream targets (Morgan, 1995) and drive the cell cycle towards G2. (Sullivan and 
Morgan, 2007) Cyclin D is unique amongst cyclins because it is not expressed 
periodically, but will be expressed as long as it is stimulated by growth factors and is 
rapidly degraded following their loss. (Assoian and Zhu, 1997; Sherr, 1994) The loss of 
cyclin D during G1, results in cells not being able to enter S-phase but if cyclin D is lost 
later in the cell cycle, it does not appear to have any effect. (Baldin et al., 1993; Quelle 
et al., 1993; Sherr, 1994) The activation of cyclin D leads to the phosphorylation of RB. 
E2F/RB is a transcription repressor and phosphorylation of pRB (Retinoblastoma 
protein) by Cdk4/Cyclin D causes a reduction in this transcriptional repression. This 
leads to expression of a number of proteins including CDC6/hCdc18 (which is essential 
for maturation of the Origin Recognition Complex) and Cyclin E. (Dyson, 1998; 
Weinberg, 1995) Cyclin E activates Cdk2, which as a consequence, further 
phosphorylates pRB resulting in its dissociation from E2F. The RB free E2F “activator” 
protein binds to the promoter regions of CDC6/hCdc18 and cyclins A and E activating 
their transcription. (Sherr and Roberts, 1999; Takahashi et al., 2000) (Figure 1-6) Cyclin 
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A also has been demonstrated to be able to phosphorylate pRb. It is also believed that 
this activity maintains the phosphorylation as the cells pass through S-phase. (Classon 
and Harlow, 2002; Morgan, 2007) The increase in transcription of cyclins A and E 
along with the inactivation of the APCCdh1 (which degrades cyclin A) allows for the 
concentration of G2 cyclins to begin to increase as the cell passes through S-phase into 
G2. (Harper et al., 2002) 
The loss of APCCdh1 allows the buildup of cyclin B/Cdk1. (Harper et al., 2002) 
However, its activity may be kept at a low level due to phosphorylation by Wee1 and 
Myt1 (as previously described). (Dunphy, 1994) As the cell progresses in G2 these 
complexes are dephosphorylated by Cdc25 (A-C), activating them. (Dunphy, 1994) 
This gives a positive feedback due to active cyclin B-Cdk1 complexes phosphorylating 
Cdc25 and the inhibitor kinases Wee1 and Myt1, activating and deactivating them 
respectively. (Domingo-Sananes et al., 2011) This results in a switch like response 
where cyclin B is generally either active or inactive (i.e. not graduated response); the 
caveat being partial activation of cyclin B-Cdk1 is required before the feedback loops 
are able to elicit a complete response. (Hoffmann et al., 1993) There is evidence 
demonstrating that cyclin A-Cdk2 complexes are able to phosphorylate Cdc25 
(activating it) as well as both Myt1 and Wee1, resulting in their inactivation.(De Boer et 
al., 2008) Proteins of the 14-3-3 group (apart from 14-3-3σ) have also been shown to be 
able to bind to Cdc25B/C that have been phosphorylated at a single binding site. The 
binding of 14-3-3 blocks Cdc25 interaction with cyclin B-Cdk1 and results in Cdc25 
being sequestered in the cytoplasm. (Gardino and Yaffe, 2011)  14-3-3σ and other 14-3-
3 isoforms are also able to bind Wee1 causing it to be evenly distributed in the nucleus. 
(Gardino and Yaffe, 2011) 
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: Diagram showing how multiple phosphorylation events are required to fully activate cyclin A and E transcription. E2F-Rb acts as a 
transcriptional repressor unless Rb is phosphorylated. Further phosphorylation causes loss of Rb and E2F can act as a transcriptional activator.
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The Chk proteins are thought to be important in the cells response to DNA damage; 
with Chk1 being predominately responsible for response to single strand breaks and 
Chk2 being predominately involved in response to double strand breaks. (Jazayeri et al., 
2006) Upon their activation, the Chk1/2 proteins have been shown to inactivate Cdc25A 
and increase the activation of Wee1, therefore preventing cells with DNA damage 
entering mitosis until the damage has been repaired. (Reinhardt and Yaffe, 2009) 
AMP-activated Protein Kinase (AMPK) directly inhibits Protein Phosphatase 1 
Regulatory Subunit 12C (PPP1R12C) by phosphorylation. (Banko et al., 2011) 
PPP1R12C is known to inhibit the function of the myosin regulatory light chain 
(MRLC) by removing activating phosphates. (Banko et al., 2011; Ito et al., 2004; 
Komatsu et al., 2000) The loss of this activation prevents cytokinesis (Banko et al., 
2011; Komatsu et al., 2000) and therefore a lack of proper cell division, resulting in an 
increase in the number of multinucleated cells.   
The active form of AMPK (pAMPK) has a role in preventing the cell passing a ‘lipid’ 
checkpoint in mitosis. (Scaglia et al., 2014)  Scaglia et al, provide evidence that the 
lipid checkpoint ensures the synthesis of fatty acids and phosphatidylcholine is available 
for the generation of new membranes. They show that pAMPK activity decreases the 
levels of Acetyl-CoA carboxylase 1 which is the rate-limiting enzyme in fatty acid 
synthesis. (Scaglia et al., 2014) The presence of pAMPK therefore results in the loss of 
de novo fatty acid synthesis and subsequently cell arrest at this point. 
 In addition to its activation, relocation of cyclin-B-Cdk1 to the nucleus is important for 
its functionality in the cell. (Pines and Hunter, 1991) In G2 and early prophase, the 
complex tends to be located in the cytoplasm before it enters the nucleus, triggering the 
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nuclear envelope to dissolve and allowing cyclin B-Cdk1 to affect nuclear targets at the 
correct time. (Morgan, 2007; Pines and Hunter, 1991)  
After the separation of chromatids, the Cdk targets that have been activated through 
phosphorylation have to be deactivated, this is the major regulatory mechanism for the 
completion of mitosis. Most of this deactivation occurs by deactivation of the Cdks so 
that phosphatases can remove the phosphates from the activated Cdk targets. This 
degradation of cyclin B is achieved using the APCCdc20 as previously described. (Harper 
et al., 2002; Peters, 2002)  The APCCdc20 is not enough to inactivate the genes activated 
by Cdk1 complexes, Cdc14 dephosphorylates cyclin B-Cdk1 and its targets, 
inactivating them. (Jaspersen et al., 1998) This results in decreased kinase activity of the 
Cdks, which turns off the downstream targets and eventually results in Cdc20 
dissociating from the APC/c (as its phosphorylation by Cdks fails to occur), to be 
replaced by Cdh1. Cdh1 binding to the APC/c completes the inactivation of Cdk1, 
returning the cell to G1 to await another round of cell division. (Harper et al., 2002; 
Morgan, 2007; Peters, 2002) 
 MYC INVOLVEMENT IN THE CELL CYCLE 
Myc is a transcription factor that binds to the promotor region of several different genes 
whose products are vital for cell cycle control and progression (Bretones et al., 2014) 
and is a known downstream target of Ras (previously described). It is able to help 
promote the G1/S transition by promoting the transcription of the cyclins and Cdks. 
Additionally it is also able to induce CAKs and Cdc25 proteins and inhibit Wee1, 
(Bretones et al., 2014) resulting in greater activation of the various cyclin Cdk 
complexes (e.g. cyclin B/Cdk1) that, as previously described, are required to allow the 
  ROBERT FERGUSON 
 
 52  
 
cells to transition from G1 to S-phase. Myc therefore provides one way for the mutation 
of K-Ras in pancreatic cancer cells to influence a key ‘Hallmark of Cancer’, cell 
proliferation. (Figure 1-34). (Hanahan and Weinberg, 2000, 2011)    
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 AIMS 
K-Ras is well known to be involved in pancreatic cancer and has several well studied 
functions. There is little previous evidence regarding the contribution of other Ras 
isoforms to the development and maintenance of PDAC. Additionally, although K-Ras 
has been identified as controlling cyclin D, there has been little research on its role 
regulating the other cyclins. The aims of this project and my initial hypotheses are 
therefore:  
 To identify if Ras isoforms other than K-Ras, are active in pancreatic cancer 
cells, and if they have any functions that differ to K-Ras. 
o Hypothesis: no other Ras isoforms are active or functional in pancreatic 
cancer cells.  
 To examine how active Ras isoforms modulate cyclin levels in PDAC cell lines 
and identify if cyclin regulation extends beyond the classical paradigm described 
for cyclin D.     
o Hypothesis: K-Ras only regulates the G2 cyclins via cyclin D in a cell 
cycle dependent manner. 
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CHAPTER 2: MATERIALS AND METHODS 
Cell lines 
Cell line Where obtained 
Suit-2  Gift from Professor Nick Lemoine, Barts 
Cancer Institute, Queen Mary University 
of London 
Panc-1 slow American Type Culture Collection 
(Middlesex, UK) 
Panc-1  American Type Culture Collection 
(Middlesex, UK) 
BxPC3 American Type Culture Collection 
(Middlesex, UK) 
MIA PaCa-2 American Type Culture Collection 
(Middlesex, UK) 
KPC mouse derived cell line Gift from Michael C Schmid University of 
Liverpool 
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Suppliers of chemicals and reagents 
Chemical or Reagent Supplier Catalogue 
number 
6-well tissue culture plates Appleton Woods, 
Birmingham 
CC010 
96-well tissue culture plates Appleton Woods, 
Birmingham 
BC015 
Albumin from Bovine Serum  Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
A4503-100G 
Amphotericin B solution Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
A2942-20ML 
Monoclonal Anti-β-Actin antibody 
produced in mouse 
Sigma Chemical Co, Poole, 
Dorset 
A5441-.2ML 
Bio-Plex Pro 27 Plex Human 
Cytokine, Chemokine and Growth 
Factor Assay  
Bio-Rad Laboratories Ltd, 
Hercules, CA, USA 
M50-0KCAF0Y 
Cyclin D1 antibody Abcam, Cambridge, Uk ab137875 
Cyclin E antibody Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-198 
Cyclin A antibody (H-432) Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-751 
Cyclin B antibody Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-752 
N-Ras antibody Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-31 
geminin (F-7) antibody Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-74456 
survivin antibody (D-8): Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-17779 
Anti-phospho-AMPK α (Thr172) 
antibody 
Merck Millipore, Watford, 
UK 
07-681 
Pierce Active Ras pulldown and 
detection Kit 
Fisher Scientific, 
Loughborough, Leicestershire 
11825015 
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Bortezomib Santa Cruz Biotechnology, 
Heidelberg, Germany 
sc-217785 
Protein assay reagent A, BCA Fisher Scientific, 
Loughborough, Leicestershire 
11881345 
Protein assay reagent B, BCA Fisher Scientific, 
Loughborough, Leicestershire 
10475944 
Cell scrapers STARLAB (UK) Ltd, Milton CC7600-0250 
15 ml Centrifuge tube, conical, loose 
(Sterile)  
STARLAB (UK) Ltd, Milton 
 Keynes,Buckinghamshire 
E1415-0200 
50 ml Centrifuge tube, conical, loose 
(Sterile)  
STARLAB (UK) Ltd, Milton 
 Keynes,Buckinghamshire 
E1450-0200 
Click-iT® EdU Alexa Fluor® 647 
flow cytometry assay kit 
Life technologies, Paisley, 
Renfrewshire 
C10424 
Dimethyl sulfoxide (DMSO) Fisher Scientific, 
Loughborough, Leicestershire 
D8418-1L 
Distilled water University of Liverpool stores  
DL-dithiothreitol (DTT) Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
D0632-5G 
Dulbecco’s Modified Eagle’s Medium 
(DMEM) 
Life technologies, Paisley, 
Renfrewshire 
31966047 
Ethanol University of Liverpool stores  
0.5 ml Eppendorf (SafeLock) 
microcentrifuge Tube 
Fisher Scientific, 
Loughborough, Leicestershire 
10292611 
1.5 ml Eppendorf (SafeLock) 
microcentrifuge Tube 
Fisher Scientific, 
Loughborough, Leicestershire 
10509691 
FACS tubes BD falcon round bottom 
polystyrene tube 5 ml with Cap 
Scientific Laboratory 
Supplies Limited, Wilford, 
Nottingham 
352054 
Foetal bovine serum (FBS) (South 
American) 
Life technologies, Paisley, 
Renfrewshire 
10270106 
GDC-0941 (PI3K inhibitor) Stratech Scientific Ltd, 
Newmarket, Suffolk 
S1036-SEL-5mg 
Glycerol Fisher Scientific, 
Loughborough, Leicestershire 
10579570 
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Glycine Fisher Scientific, 
Loughborough, Leicestershire 
10607443 
Goat anti-mouse immunoglobulin 
HRP 
Dako Ltd, High Wycombe, 
Buckinghamshire 
DAKO P0447 
Goat anti-rabbit immunoglobulin HRP Dako Ltd, High Wycombe, 
Buckinghamshire 
DAKO P0448 
Hs_CCNA2_1_SG QuantiTect primer 
Assay 
Qiagen Ltd, Manchester, UK QT00014798 
Hs_CCNB1_1_SG QuantiTect primer 
Assay 
Qiagen Ltd, Manchester, UK QT00006615 
Hs_GAPDH_1_SG QuantiTect primer 
Assay 
Qiagen Ltd, Manchester, UK QT00079247 
Hydrochloric acid University of Liverpool stores  
Carestream® Kodak® 
autoradiography GBX developer 
Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
P7042-5GA 
Carestream® Kodak® 
autoradiography GBX 
fixer/replenisher 
Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
P7167-5GA 
L-Glutamine solution Bioxtra, 200 
MM 
Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
G7513-100ML 
LightCycler 480 Sybr Green master 
mix 
Roche Diagnostics Ltd, West 
Sussex 
4707494001 
LightCycler 480 plates 96 well Roche Diagnostics Ltd, West 
Sussex 
4729692001 
Lipofectamine (15 ml)  Life technologies, Paisley, 
Renfrewshire 
11668500 
Mini Protean® Tetra System/AnyKD 
gels 
BioRad, Hemel Hempstead, 
Hertfordshire 
456-9033 
Mini Protean® Tetra System/ TURBO 
PVDF MINI, 10 
BioRad, Hemel Hempstead, 
Hertfordshire 
170-4156 
Non-fat Dry Milk – blotting grade BioRad, Hemel Hempstead, 
Hertfordshire 
170-6404   
Nucleocounter solution A ChemoMetec A/S Allerod, 
Denmark 
910-0003 
Nucleocounter solution B ChemoMetec A/S Allerod, 910-0002 
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Denmark 
Nucleocounter cassettes ChemoMetec A/S Allerod, 
Denmark 
940-0002 
Nunc flask T25 vented Fisher Scientific, 
Loughborough, Leicestershire 
12034917 
Nunc flask T75 vented Fisher Scientific, 
Loughborough, Leicestershire 
10364131 
Nunc flask T175 vented Fisher Scientific, 
Loughborough, Leicestershire 
10246131 
Opti-MEM® I Life technologies, Paisley, 
Renfrewshire 
31985-062 
PD0325901 (MEK inhibitor) Stratech Scientific Ltd, 
Newmarket, Suffolk 
S1036-SEL-5mg 
Penicillin-streptomycin Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
P0781-100ML 
Phosphate Buffered Saline (PBS) 
Tablets 
Fisher Scientific, 
Loughborough, Leicestershire 
10388739 
Phosphate Buffered Saline (PBS) 
(Sterile used for cell culture) 
Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
20012019 
10x Phosphate Buffered Saline (PBS) 
(non sterile) 
Fisher Scientific, 
Loughborough, Leicestershire 
10214733 
Corning 5 ml pipettes Appleton Woods, 
Birmingham 
CC208 
Corning 10 ml pipettes Appleton Woods, 
Birmingham 
CC214 
Corning 25 ml pipettes Appleton Woods, 
Birmingham 
CC216 
10 µl graduated tip, refill Starlab, Milton Keynes, 
Buckinghamshire 
S1111-3700 
200 µl yellow bevelled tip, refill Starlab, Milton Keynes, 
Buckinghamshire 
S1111-1706 
1000 µl  blue graduated tip, refill Starlab, Milton Keynes, 
Buckinghamshire 
S1111-6701 
 
1-200ul round gel loading tip, racked 
 
Starlab, Milton Keynes, 
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(sterile) Buckinghamshire I1022-0610 
10 µl XL graduated filter tip (sterile) Starlab, Milton Keynes, 
Buckinghamshire 
S1120-3810 
20 µl bevelled filter tip (Sterile) Starlab, Milton Keynes, 
Buckinghamshire 
S1120-1810 
200 µl graduated filter tip (Sterile) Starlab, Milton Keynes, 
Buckinghamshire 
S1120-8810 
1000 µl XL filter tip (Sterile) Starlab, Milton Keynes, 
Buckinghamshire 
S1122-1830 
Pre-diluted protein assay Standard 
(BSA V) Set 
Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
1053-1674 
Propidium Iodide Sigma Chemical Co, Poole, 
Dorset 
P4170-10MG 
Protease inhibitor tablets, EDTA-free Roche, Welwyn Garden City, 
Hertfordshire 
11422900 
Protein ladder Life technologies, Paisley, 
Renfrewshire 
26617 
Reagent reservoirs STARLAB (UK) Ltd, Milton E2310-1010 
QuantiTech reverse transcription kit Qiagen Ltd, Manchester, UK 205311 
RNase A/T1 Mix Fisher Scientific, 
Loughborough, Leicestershire 
EN0551 
RNeasy Mini Kit Qiagen Ltd, Manchester, UK 74104 
RPMI-1640 media Sigma Chemical Co, Poole, 
Dorset 
R0883-
6X500ML 
RPMI-1640 media 10x bicarbonate 
free 
Sigma Chemical Co, Poole, 
Dorset 
R1145-500ML 
SMARTpool: ON-TARGETplus 
CCND1 siRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
L-003210-00-
0010 
SMARTpool: ON-TARGETplus 
RALA siRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
L-009235-00-
0005 
SMARTpool: ON-TARGETplus 
RALB siRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
L-008403-00-
0005 
SMARTpool: ON-TARGETplus N-
Ras siRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
L-003919-00-
0010 
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SMARTpool: ON-TARGETplus K-
Ras siRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
L005069-00-
0020 
ON-TARGETplus KRAS ORF siRNA GE healthcare/Dharmacon 
Lafayette, CO, USA 
J-005069-10-
0050 
ON-TARGETplus KRAS  3’-UTR 
SIRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
J-005069-11-
0050 
ON-TARGETplus KRAS ORF siRNA GE healthcare/Dharmacon 
Lafayette, CO, USA 
J-005069-08-
0050 
ON-TARGETplus KRAS UTR, ORF 
siRNA 
GE healthcare/Dharmacon 
Lafayette, CO, USA 
J-005069-09-
0050 
ON-TARGETplus Non-targeting Pool GE healthcare/Dharmacon 
Lafayette, CO, USA 
D-001810-10-05 
ON-TARGETplus RISC free control GE healthcare/Dharmacon 
Lafayette, CO, USA 
D-001600-01-05 
Sodium chloride Fisher Scientific, 
Loughborough, Leicestershire 
10428420 
Sodium dodecyl sulphate (SDS) Fisher Scientific, 
Loughborough, Leicestershire 
10607443 
Sodium hydroxide VWR, Lutterworth, 
Leicestershire 
10396240 
Supreno, blue, powder-free nitrile 
gloves 
Starlab, Milton Keynes, 
Buckinghamshire 
SU-INT-M 
Trypsin-EDTA solution Sigma Chemical Co, Poole, 
Dorset 
T3924-100ML 
TC10 cell counting slides BioRad, Hemel Hempstead, 
Hertfordshire 
145-0011 
Tris base Fisher Scientific, 
Loughborough, Leicestershire 
10376743 
Triton X-100 Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
X100-100ML 
Tween® 20 Sigma-Aldrich Company Ltd, 
Gillingham, Dorset 
P1379-500ML 
Ubiquitin enrichment kit Fisher Scientific, 
Loughborough, Leicestershire 
10158023 
Virkon   Fisher Scientific, HYG-205-021K 
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Loughborough, Leicestershire 
Western lightning plus ECL Life technologies, Paisley, 
Renfrewshire 
31985-062 
X100 FUJI RX X-Ray film Fisher Scientific, 
Loughborough, Leicestershire 
1271-5325 
XF24 flux pak (seahorse kit) Seahorse BioSciences order 
online at 
seahorsebiostore.com 
100850-001 
 
Suppliers of equipment 
Branson sonicade Branson Ultrasonics Co, 
Shangai, China 
Bio-Plex 200 System Bio-Rad Labororatories Ltd, 
Hercules, CA, USA 
Bio-Plex Pro wash station Bio-Rad Labororatories Ltd, 
Hercules, CA, USA 
Bio-Plex manager 5.0 Software Bio-Rad Labororatories Ltd, 
Hercules, CA, USA 
DC126291 Camera Canon 
Eppendorf Biophotometer Fisher Scientific, 
Loughborough, Leicestershire 
FACSDiva software version 7 Beckton Dickinson, Oxford, 
Oxfordshire 
FlowJo version 7 TreeStar, Inc., Ashland, OR 
Mr. Frosty™ freezing container Thermo Scientific, 
Loughborough, Leicestershire 
Heraeus Biofuge primo Centrifuge Thermo Scientific, 
Loughborough, Leicestershire 
Heraeus Pico17 mini Centrifuge Thermo Scientific, 
Loughborough, Leicestershire 
Procell incubator Jencons Scientific Ltd, Leighton 
Buzzard, Bedfordshire 
JB Aqua 26 plus water bath Grant, Shepreth, Cambridgeshire 
  ROBERT FERGUSON 
 
 62  
 
 
LightCycler 480  
 
Roche Diagnostics Ltd, West 
Sussex 
LSRFortressa™ flow activated cell 
sorter 
Beckton Dickinson, Oxford, 
Oxfordshire 
Nanodrop spectrophotometer Thermo Scientific, 
Loughborough, Leicestershire 
Nucleocounter ChemoMetec A/S Allerod, 
Denmark 
Seven compact pH meter Mettler-Toledo, Beaumont Leys, 
Leicestershire 
Dry bath heating system STARLAB (UK) Ltd, Milton 
Keynes,Buckinghamshire 
  
TC10™ automated cell counter BioRad, Hemel Hempstead, 
Hertfordshire 
Trans-Blot® turbo™ transfer system BioRad, Hemel Hempstead, 
Hertfordshire 
Vortex genie 2 Scientific Industries, New York 
Weighing scales VWR, Lutterworth, 
Leicestershire 
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Preparation of solutions 
1M DL-Dithiothreitol (DTT) 
0.154 g DTT 
1 ml distilled water 
Storage: Aliquoted and stored at -20°c 
 
1M Tris 
30.29 g Tris HCl 
200 ml distilled water 
pH as required 
Storage: Room temperature 
 
Dark Room Developer (Kodak®) 
210 ml Carestream® Kodak® autoradiography GBX developer 
 790 ml H20 
 
Dark Room Fixer (Kodak®) 
210 ml Carestream® Kodak® autoradiography GBX Fixer/replenisher 790 ml H20 
 
RNAse (10mg/ml) 
100 mg RNAse 
10 ml PBS 
Storage: Aliquoted and stored at -20°c 
 
Propidium iodide (1mg/ml) 
10 mg Propidium iodide 
10 ml PBS 
Storage: Aliquoted and stored at -20°c 
 
Running Buffer x10 
50 ml 20% Sodium dodecyl sulphate (SDS) 
144 g Glycine 
30 g Tris Base 
Make up to 1 L with distilled water 
Storage: Room temperature 
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PBST x1 
10 phosphate buffered saline (PBS) tablets 
1 L distilled water 
1 ml Tween per 0.1% concentration desired 
Storage: Room temperature 
Reducing Sample Buffer x5 
1 g Sodium dodecyl sulphate (SDS) powder 
3 ml 1M Tris HCl pH 6.8 
5 ml Glycerol 
2 ml distilled water 
0.05 g bromophenol blue 
Storage: Aliquoted and stored at -20°c 
 
RIPA Buffer 
2 ml 1M Tris (pH7.5) 
5 ml 3M NaCl 
1 ml IGEPAL 
200 μL 0.5 EDTA 
91.8 ml dH20 
Storage: Aliquoted and stored at 4°c 
1x Inhibitor tablet per 10ml (added when being used) 
 
10x Tris buffered saline 
87.66 g NaCl 
121 g Tris 
Make up to 1 l with distilled H2O 
pH to 7.5 
Storage: Room temperature 
 
Freeze media 
5 ml RPMI-1640 (10% FBS + 1% L Glutamine) 
 500 µl DMSO 
 
Stripping Buffer 
10 ml SDS (20%) 
12.5 ml 1M TRIS HCL pH = 6.5   
700 μL Mecaptethanol 
76.8 ml H20 
Storage: Room temperature 
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 CELL CULTURE 
The human pancreatic cell lines MIA PaCa-2, BxPC3, Panc-1 and Suit-2 were used. 
These cell lines were cultured at 37oC with 5% CO2 in RPMI-1640 media that had 10% 
foetal bovine serum and 1% L-glutamine added.  The cells were passaged every two to 
three days when at 80-90% confluency. A mouse cell line derived from a KPC mouse 
tumour was also used in this work. It was cultured at 37oC with 5% CO2 in DMEM that 
had 10% foetal bovine serum, 1% L-glutamine, 1% penicillin/streptomycin and 1% 
amphotericin B. The cells were passaged every 2-3 days when at 80-90% confluency. 
 HARVESTING OF CELLS FOR OPTIMISATION OF WESTERN BLOT 
A 90% confluent T75 flask of cells was used to generate cell lysates for optimisation of 
K-Ras detection by western blot. These cells were washed with PBS, which was then 
discarded. 10 ml of PBS was then added and the cells were scraped off the bottom of 
the flask using a cell scraper. The cell suspension was then transferred to a 15 ml falcon 
tube and spun at 1000 g for 10 minutes in a bench top centrifuge. The supernatant was 
removed ensuring that the cell pellet was not disturbed. The cell pellet was then stored 
at -80oC until cell lysates were made for western blotting. 
 HARVESTING OF CELLS FOLLOWING SIRNA TREATMENT FOR WESTERN 
BLOT 
Cells treated with siRNA were grown in 6 well plates see Table 1: . Each well had the 
media aspirated off and 1 ml of cold PBS added to the well. Using a cell scraper the 
cells were scraped off the bottom of the well. The cell suspension was then transferred 
to a 1.5 ml microcentrifuge tube and spun in a microcentrifuge for 10 minutes at 1000  
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g. After centrifugation the supernatant was removed, the contents of another well 
treated with the same conditions could then be added and the process repeated (if 
required). Once the cell pellet had been obtained it was stored at -80oC until cell lysates 
were prepared. 
 PREPARATION OF CELL LYSATES FOR WESTERN BLOT 
The cell pellets that had previously been frozen at -80oC were defrosted on ice before 
removing any excess liquid that remained without disturbing the pellet. The cell pellet 
was then resuspended in RIPA buffer and placed on ice. The suspension was then 
sonicated in a Branson Sonicade for 5 seconds at 30% output with continuous pulse. 
Following sonication the cells were kept on ice before being transferred to a 
microcentrifuge at 4oC and spun at 16434 g for 10 minutes. The supernatant was then 
transferred to a microcentrifuge tube and stored on ice. 
 QUANTIFICATION OF TOTAL PROTEIN USING THE BICINCHONINIC ACID 
ASSAY 
Protein was quantified using the BCA assay with the standards and working reagent 
being made up following the protocol in the BCA assay manual.  Each sample to be 
measured was diluted 1:10 (5 µl in 45 µl of lysis buffer). 50 µl of each standard and 
each diluted sample was then added to 9950 ml of working reagent. These were then 
left at 37oC for approximately 25 minutes before being read on an Eppendorf 
bioPhotometer using the BCA micro program. 
  ROBERT FERGUSON 
 
 67  
 
 WESTERN BLOT 
An identical quantity of protein was loaded into each well of a TGX AnyKD precast gel 
and a voltage of 300 volts was applied until the marker dye had separated suitably 
(approximately 15 minutes). Once run, the gel was removed from its plastic casing and 
placed on pre-prepared PVDF membrane. The sample was loaded into the Bio-Rad 
turbo blotter and transferred using the high molecular weight program pre-programmed 
by Bio-Rad (1.3 amp, 25 volts, and 10 minutes). Once transferred the membrane was 
blocked in 5% milk (non-fat blotting grade) in PBST (1x PBS, 0.1% Tween) for three 
hours rocking at room temperature. The primary antibody (diluted in 5% milk, 
0.1%PBST) was added and left overnight rocking at 4oC.  Following incubation with 
the primary antibody the membrane was washed three times for 10 minutes with PBST 
at 37oC. After washing, the secondary antibody (diluted in 5% milk, 0.1%PBST) was 
applied and left for 60 minutes rocking at room temperature. The membrane was 
washed six times for 10 minutes with warm (37oC) 0.1% PBST before being visualised 
using chemoluminesce and X-ray film. The position of the size markers on the western 
blot was recorded using tracker tape. Tracker tape is luminescent and marks the X-ray 
film allowing for the protein of interest to be compared to the size makers (Figure 2-1). 
If another antibody was to be tested the membranes were then stripped for 20 minutes at 
50oC using harsh stripping buffer before being washed with distilled water. The same 
process as described above for the initial antibody was repeated for any further 
antibodies. 
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: Example western blot demonstrating how size markers were compared 
to the lanes of interest. Size markers positions on the western blot were recorded 
using tracker tape.    
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  SIRNA TREATMENT OF CELL LINES 
Cells were seeded into six well plates at the seeding densities shown in Table 1:  and 
left over night in RPMI-1640 at 37oC with 5% CO2. After 24 hours the RPMI-1640 
media was removed and replaced with a further 2.5 ml of RPMI-1640 media. 200 µl of 
Opti-MEM I containing 4 µl Lipofectamine 2000 and 200 µl of Opti-MEM I containing 
the siRNA Table 2:  of interest were incubated at room temperature for 5 minutes before 
being mixed together and incubated for a further 30 minutes at room temperature. This 
solution was then added drop wise to each well and the plates were put at 37oC with 5% 
CO2 until harvesting.  Each knockdown experiment initially required 3 controls 
(although only the non-targeting control was used if they showed the same result in 
subsequent experiments), which are described in Table 3: . 
Cell Line Seeding density (cells/ml) 
Suit-2 1x105 
Panc-1 1x105 
MIA PaCa-2 2.5x105 
Table showing density that cells were seeded at in each well of a six well plate 
for siRNA experiments 
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siRNA Concentration 
K-Ras 10 nmol 
N-Ras 100 nmol 
Cyclin D 10 nmol 
Ral A 10 nmol 
Ral B 10 nmol 
 Concentrations of siRNA used to treat cells seeded in a six well plate.  
 
 
 
Control  Type of control 
Lipofectamine only control Control without any siRNA to show that 
the transfection procedure had no effect on 
the gene of interest 
RISC free control siRNA is chemically modified to prevent 
processing by the RISC complex. 
Therefore, demonstrates any effects are 
not caused by the siRNA mechanism 
Off target control siRNA does not target any genes in the 
genome and therefore any effect on the 
gene of interest is due to off target effects 
Controls used for siRNA experiments  
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 GROWTH CURVE EXPERIMENTS 
Cells were set up in 6 well plates and knocked down using KRAS siRNA as previously 
described in section 2.7. For each time point to be examined 6 wells were set up 
containing the siRNA of interest and 4 wells were set up for each of the 3 controls 
(Lipofectamine only, Off target control and RISC free control). After 48hrs the cells 
were reseeded into T25 culture flasks and 10 ml of RPMI-1640 growth media was 
added. After 144 h the cells were split with a 1 in 4 dilution. This was done to prevent 
the cells overgrowing. The media was refreshed every 48 h when the cells had not been 
reseeded or split. Once set up 5 wells of the siRNA knockdown and 3 wells of each 
control were harvested for western blot analysis at 48, 96, 144, 192 and 216 hour time 
points following the same method as described in section 2.6. The final well of 
knockdown and the 3 controls were harvested and tested as described below. 
 HARVESTING AND TESTING CELL VIABILITY  
The media from the well/flask was removed and spun down at 1000 g for 5 minutes.  
After centrifugation the supernatant was removed and the process was repeated until all 
the media had been spun down in the same microcentrifuge tube. Once all of the media 
had been removed 2 ml of PBS was added to the well/flask and left at 37oC for 
approximately 5 minutes. The PBS was then removed and spun down into the same 
microcentrifuge tube. 2 ml of trypsin was added to each well/flask and left at 37oC until 
all of the cells had detached. The cell/trypsin suspension was then spun down in the 
same microcentrifuge tube as the media and PBS previously, this allows for all the cells 
dead or alive to be collected from each well/ flask. The cell pellet from these spins was 
resuspended in 1 ml of media and 200 µl was used for the viable and nonviable cell 
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counts. To determine the viable and nonviable cell count the Nucleocounter was used. 
For the total cell count 200 µl of Nucleocounter solution A and B were added to the 200 
µl of cells and then the solution was taken up into a Nucleocounter cassette and 
measured using the Nucleocounter. This was done in duplicate and the mean value was 
calculated. The nonviable cell count was determined using the 200 µl cell suspension, 
without any other solutions, this was also done in duplicate and an average taken. The 
Nucleocounter provides its cell counts in cells/ml and since only 1 ml was available per 
well no dilutions need to be accounted for. Therefore the percentage viability is 
determined using the formula: 
 
 FACS ANALYSIS OF SAMPLES 
 PROPIDIUM IODIDE TREATMENT OF CELLS FOR CELL CYCLE ANALYSIS 
Samples were prepared in six well plates for FACS analysis, one well used per analysis. 
Knockdowns were done as described in section 2.7.  The media was removed from the 
well and the cells were washed with 2x volume of PBS to remove any unattached cells. 
300 µl of trypsin was added to each well and then left at 37oC until the cells detached. 
Once the cells have detached 1 ml of media was added and the cell suspension was 
transferred to a 15 ml conical tube.  The cell suspension was centrifuged at 500 g (4oC) 
for 5 minutes and after centrifugation the supernatant was aspirated off. The cell pellet 
was washed with 1 ml of PBS and centrifuged at 500 g (4oC) for 5 minutes. The PBS 
was then aspirated off (apart from a few drops which were used to start the resuspension 
of the cell pellet) before adding 2 ml of ice cold ethanol drop wise; vortexing to ensure 
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that the cells were fully resuspended. The samples were then stored for a minimum of 
16 hours at 4oC to allow the cells to fix (note they could have been stored for weeks 
with no detriment to the result).  
On the day the FACS analysis was to be carried out the samples were centrifuged at 500 
g (4oC) for 5 minutes and the supernatant aspirated and discarded. 500 µl of propodium 
iodide (50 µg/ml) and 50 µl of RNase (10mg/ml diluted 1:10 in PBS) were added to the 
sample before mixing by tapping gently and incubation in the dark at room temperature 
for 15 minutes.  The sample was then transferred to a FACS tube and run on the FACS 
machine following the Good Clinical Laboratory Practice Facility SOPs 
GCLPEQU028/v1 and GCLPTSS092/v1. A minimum of 10000 cells were analysed 
using sequential gating. The 1st gate using forward scatter-area vs Forward scatter-
height was to exclude doublets and clumps and the second gate was set on Forward 
scatter-area vs side scatter-area to exclude debris. The data was analysed using the 
software FlowJo version 7 and the analysis was performed on the cell cycle analysis 
platform using the Dean Jett Fox model. FlowJo offers two mathematical models to 
analyse cell cycle data. Both models fit Gaussian curves to G1 and G2. The Dean-Jett-
Fox model fits S-phase to a second degree polynomial and the other model makes no 
assumptions on the shape of S-phase distribution. I tried both models and selected the 
Dean-Jett-Fox model for fitting the distribution of my cell cycle results as it gave a 
value for S-phase that fitted better with my impression of the raw histogram 
representations. 
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 S-PHASE LABELLING OF CELLS USING EDU 
Samples were prepared in six well plates for FACS analysis, one well used per analysis. 
The cells were treated with siRNA as described in section 2.7. Cells were treated with 
EdU (10mM) at either 24,26,28,30 or 32 h post siRNA treatment. The cells were then 
grown until 48 h after which the media was removed and 1 ml of PBS added to each 
well. The cells were scraped into the PBS before being transferred to a 15 ml falcon 
tube (15 ml falcon tubes rather than microcentrifuge tubes as this improved recovery of 
cells after subsequent centrifugation steps). The cells were spun at 1000 g for 10 
minutes and the PBS was aspirated off. Each sample was washed with 1 ml 1% FBS in 
PBS before being spun again for 10 minutes (1000 g) and removing the supernatant. 
The pellets were then resuspended in 100 µl of Click-iT fixative (from the Click-iT® 
EdU Alexa Fluor® 647 flow cytometry assay kit) and incubated at room temperature 
for 15 minutes in the dark. The cells were then washed with 3 ml 1% FBS in PBS 
before being spun again for 10 minutes (1000 g) and then the supernatant was removed.  
The cell pellet was then resuspended in 100 µl of Click-iT saponin-based 
permeabilization and wash reagent and incubated for 15 minutes in the dark as before. 
While incubating during the previous step the Click-iT EdU reaction cocktail was 
prepared according to Table 4 . After the previous incubation has been completed 0.5 
ml of the Click-iT EdU reaction cocktail was added to each sample, which was then 
incubated in the dark at room temperature for 30 minutes. The cells were washed once 
with 3 mls of the saponin-based permeabilization and wash reagent, spun for 10 minutes 
(1000 g) before resuspending the cells in 500 µl PI solution (propodium iodide (50 
µg/ml) and 50 µl of RNase (10mg/ml diluted 1:10 in PBS) the cells were then incubated 
in the dark on ice for 15minutes.  The sample was then transferred to a FACS tube and 
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run on the FACS following the Good Clinical Laboratory Practice Facility SOPs 
GCLPEQU028/v1 and GCLPTSS092/v1. A minimum of 10000 cells were analysed 
with appropriate gating. The analysis was performed using the FACS Diva version 7 
software.  
Reaction component Volume for one reaction 
PBS 438 µl 
CuSO4 10 µl 
Fluorescent dye azide 2.5 µl 
Reaction buffer additive 50 µl 
Total reaction volume 500 µl 
Reaction mixture for EdU staining. 
 
 PREPARATION OF CELLS FOR ANALYSIS BY THE SEAHORSE BIOANALYSER 
Cells were seeded into the Seahorse specific 24 well plates Table 5:  and left for 24 h at 
37oC (5% CO2) before treatment with siRNA  (if appropriate). After 24 h the media was 
removed and 0.5 ml of RPMI-1640 with 10% Foetal bovine serum and 1% L-glutamine 
was added to the wells. siRNA was prepared as previously described (see section 2.7) 
but only 15 µl of the siRNA mixture was added to each well. The cells were then left 
for 48 h at 37oC (5% CO2). The Seahorse cartridge to be used was hydrated the day 
before the run by adding 1 ml of Seahorse calibration solution to each well of a 24 well 
plate and leaving the seahorse cartridge to equilibrate overnight at 37oC with no CO2. 
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The media was removed from the wells and 450 µl of Seahorse media was added (500 
ml Bicarbonate free RPMI-1640 with 10mM glucose 2mM sodium pyruvate and 1% L-
glutamine pH 7.4). The plate was then incubated for one hour at 37oC with no CO2. 
Each drug was diluted in Seahorse media before being loaded into the injection ports of 
the Seahorse cartridge Table 6: .  The seahorse cartridge and plate were then added to 
the Seahorse Bioanalyser and run according to the programmed settings for an Aerobic 
stress test.  
 
Number of cells to be seeded per well in a 24 well Seahorse Bioanalyser plate  
 
Drug Concentration  Volume loaded 
into injection  
port 
Injection port the 
drug was loaded in 
Oligomycin 1 µg/ml 50 µl A 
FCCP  
 (carbonyl cyanide 4‐
(trifluoromethoxy) 
phenylhydrazone) 
0.5mM 55 µl B 
Rotenone and Antimycin 
A (both drugs prepared 
together) 
Both at 1 µM 62 µl C 
Concentration and volume of drugs loaded into the injection ports of the 
Seahorse Bioanalyser  
 
Cell line Number of cells seeded per well in a 
Seahorse 24 well plate 
Panc-1 12000 
Suit-2 6000 
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 PREPARATION OF CELLS FOR LIPID ANALYSIS  
Six well plates were seeded with Suit-2 cells. The cells were treated with KRAS siRNA 
at the previously optimised concentration and the controls were treated with the same 
concentration of control siRNA. The cells will then be left for 48 hours at 37oC 5% CO2 
before being harvested.  To harvest the cells the media was aspirated off and the cells 
were washed with 3 ml of cold PBS before adding 1 ml of cold PBS to each well. The 
cells were then scraped into the PBS and transferred to a microcentrifuge tube, which 
was spun at 1000 g for 10 minutes. The supernatant was aspirated off and the process 
repeated until all the cells with the same treatment were pelleted in one microcentrifuge 
tube. The cells were then stored at -80oC before being sent to on dry ice to Professor 
Swinnen (Department of Oncology, University of Leuven) for lipid analysis.  
  PULLDOWN ASSAYS 
 ACTIVE RAS PULLDOWN 
The samples were prepared in six well plates with 4 plates being required per condition 
to generate enough protein of subsequent western blot analysis. Knockdowns were done 
as in section 2.7 and left for 48hr at 37oC (5% CO2). Media was aspirated from the 
plates and 1 ml of cold TBS was added to each well. The cells were scraped into the 
TBS before pooling wells with the same knockdown conditions into a 50 ml Falcon 
tube which was then centrifuged at 1000 x g for 10 minutes. The supernatant was 
aspirated off and the cell pellet was resuspended in 1 ml of SDS free lysis buffer, which 
was supplied by the manufacturer.  The sample was vortexed briefly before being left 
on ice for 15 minutes to lyse. The lysate was spun for 15 minutes at 4oC at 16434 g 
before the supernatant was transferred to fresh microcentrifuge tubes and kept on ice. 
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The protein concentration of the samples was determined using the BCA assay as 
describe in section 2.5. 
For each sample 100 µl of 50% glutathione resin was added to a spin cup supplied by 
the manufacturer and then centrifuged at 6000 g for 30 seconds. The flow through was 
discarded and the spin cup was washed with 400 µl of lysis buffer before spinning again 
at 6000 g for 30 seconds and discarding the flow through. 80 µg of GST-Raf1-RBD was 
then added to the spin cup before 500 µl of lysis buffer containing 500 µg of protein 
was added. The sample was vortexed and incubated for 1 hour at 4oC with gentle 
rocking. After incubating for 1 hour the samples were centrifuged at 6000 g for 30 
seconds and the flow through discarded. Each sample was washed 3 times with 400 µl 
lysis buffer centrifuging at 6000 x g for 30 seconds discarding the flow through between 
the washes. 50 µl of 2 x SDS Sample buffer was added to each spin cup and incubated 
for 2 minutes at room temperature before being centrifuged at 6000 g for 2 minutes into 
a fresh microcentrifuge tube. The spin cup was discarded and the sample stored at -20oC 
until it was to be analysed by western blot.    
 UBIQUITIN PULLDOWN 
The samples were prepared in six well plates with a minimum of four plates being 
required per condition. Knockdowns were done as in section 2.7 with 8 plates being 
prepared for each knockdown condition. The plates were incubated at 37oC (5% CO2).  
24 hours post knockdown four plates from each condition were treated with bortezomib 
(10nM) or DMSO (equivalent amount to the volume used with the drug) in 500 µl of 
RPMI-1640 with 10% FBS. Cells were harvested 48 hours post siRNA treatment and 
lysed following the lysis protocol described in section 2.12.1. Once the protein lysate 
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had been prepared the concentration was determined using the BCA assay following the 
protocol in section 2.5. 
For each sample 200 µg of protein was made up to 500 µl and was then added to a spin 
column. 20 µl of Polyubiqutin Affinity Resin from the ubiquitin pulldown kit was added 
to each sample and the samples were incubated at 4oC for two hours on a rotating 
wheel. After being left at 4oC the column was centrifuged for 15 seconds at 5000 g and 
the flow through was discarded. Three washes using 300 µl of wash buffer were 
performed centrifuging at 5000 g for 15 seconds and discarding the flow through after 
each spin. Each spin column was placed in a collection tube and 75 µl of sample buffer 
was then added. The samples were heated to 95oC for ten minutes before a final 
centrifuge step for one minute at 5000 g. The collection tubes were closed and stored at 
-20oC until they were to be analysed via western blot. 
 TRANSCRIPTIONAL ANALYSIS 
 PREPARATION AND HARVESTING OF SAMPLES 
Cells were seeded (2 wells of a 6 well plate per condition) and treated with K-Ras, 
cyclin D or non-targeting siRNA as described in section 2.7. 48 hours post siRNA 
treatment the media was aspirated off and 1 ml of PBS was added to each well. The 
cells were scraped into the PBS and wells containing the same treatment were pooled. 
The samples were then centrifuged at 1000 g for 10 minutes before removing the 
supernatant and storing the pellet at -80oC until it was needed for RNA extraction. 
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 PREPARATION OF RNA 
The samples were prepared using an RNAeasy Mini Kit. 300 µl of buffer RLT was 
added to the cell pellet before spinning at 13300 g for three minutes. The supernatant 
was transferred to a microcentrifuge tube and 300 µl of 70% ethanol was added. The 
sample was then transferred to an RNAeasy spin column and centrifuged for 15 seconds 
at 8000 g. The flow through was discarded and the column was washed by adding 700 
µl of buffer RW1 before spinning at 8000 g for 15 seconds. The process was repeated 
with 500 µl of buffer RPE and then again with another 500 µl of buffer RPE. After the 
second addition of RPE the sample was centrifuged for two minutes instead of 15 
seconds at 8000 g.  The column was then dried by discarding the flow through and re-
spinning the column for one minute at 13300 g. The spin column was placed in a fresh 
collection tube and 50 µl of molecular biology grade water was added to the column. 
This was centrifuged at 8000 g for one minute and the elute was collected. Levels of 
RNA were quantified using a Nanodrop spectrophotometer and the samples were stored 
at -80oC until they were needed to make cDNA.  
 PREPARATION OF CDNA 
The samples were prepared using the QuantiTech Reverse Transcription kit from the 
RNA prepared as in section 2.13.2. gDNA wipe out was assembled for each sample in a 
PCR tube following the recipe in Table 7: . 
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Reagent Volume/ reaction 
Wipe-out Buffer 7x 2 µl 
Total RNA Up to 1 µg 
RNAse free water Make up to 14 µl 
Total reaction volume 14 µl 
Recipe for preparing the sample for DNA wipe-out treatment 
 
The samples were then incubated at 42oC for two minutes before adding to the final 
reverse transcriptase mix following the recipe described in Table 8: . The samples were 
then incubated for 20 minutes at 42oC followed by three minutes at 95oC.  The samples 
were then stored at -20oC until they were to be used for qPCR. 
Reagent Volume/reaction 
Reverse transcription enzyme 1 µl 
Reverse transcription buffer 5x 4 µl 
Reverse transcription primer mix 1 µl 
Total volume of RNA mix 14 µ1 
Total reaction volume 20 µ1 
  Table showing the recipe for preparing the reverse transcriptase reaction 
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 QPCR 
qPCR reactions are prepared as shown in Table 9:  for each sample and includes a 
control that has the DNA template replaced with sterile H2O. Once prepared and loaded 
into a 96 well plate the samples were run on the Roche Light Cycler 480 for 50 cycles 
using the protocol in below Table 10:  
GAPDH was used to normalise between samples with the delta Ct values being the 
comparator used between samples. 
 
Reagent Volume/ reaction 
LightCycler 480 Sybr Green Master Mix 18 µl 
H2O  7 µl 
Primers 2 µl total (either 1 µl of forward and 
reverse primer or 2 µl if premixed) 
cDNA from step 2.13.3 2 µl 
 Recipe for preparing qPCR samples 
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 Step Repetitions Temperature Time 
Enzyme Activation 1 1 95oC 10 minutes 
PCR cycle 2 50 95oC 
60oC 
15 seconds 
1 minute 
Melt curve 3    
 PCR protocol used for Real-Time PCR. 
 
 MEASUREMENT OF CYTOKINES 
Suit-2 cells were seeded in a 6 well plate and treated with KRAS, NRAS, KRAS with 
NRAS or Cyclin D siRNA as described in section 2.7 and then they were left for 48 
hours at 37oC, 5% CO2. After 48 hours 1 ml of the media was aspirated and stored in a 
microcentrifuge tube at -80oC until it was required. The levels of 27 cytokines were 
measured using the Bio-Plex Pro 27 Plex Human Cytokine, Chemokine and Growth 
Factor Assay (referred to as: 27 plex), on the Bio Plex 200 System using the Bio-Plex 
Manager 5.0 software to perform the initial concentration measurements and data 
analysis. To perform the analysis 50 µl of serially diluted standards and a media blank 
were added the 27 Plex plate which contains magnetic antibody- coupled beads for each 
of the 27 analytes. To create the serially diluted standards a known amount of 
lyophilized standard was reconstituted with 500 µl of tissue culture medium. This was 
vortexed for 1-3 seconds and incubated on ice for 30 minutes. 8 microcentrifuge tubes 
were labelled 1-8 and 72 µl of culture media was added to microcentrifuge tube 1 with 
50 µl of culture media being added to each of the remaining tubes. Following the 30 
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minute incubation on ice 128 µl of stock standard was added to microcentrifuge tube 1. 
This was then vortexed briefly and 50 µl was transferred to microcentrifuge tube 2, this 
process repeated with 50 µl being added from the previous sample until microcentrifuge 
tube 8 was reached. Once the test samples were added the plate was incubated at room 
temperature under constant agitation (900 rpm) for one minute and then for 30 minutes 
at room temperature with agitation (300 rpm). The plates were washed on the Bio-Plex 
Pro Wash Station before adding 25ul of the secondary antibodies to each well and 
incubating at room temperature as before. After the incubation period the plate was 
again washed using the Bio-Plex Pro Wash station and then 50 µl of Streptavidin-PE 
was added. The plate was then incubated at room temperature again but the 300 rpm 
step was changed to 10 minutes. Assay buffer (125 µl) was added to each well and the 
samples were read on the Bioplex 200. The fluorescent intensities of each of the 27 
cytokine, chemokines or growth factors were converted to pg/ml by comparing the 
obtained values to a standard curve.  
 STATISTICAL METHODS 
All statistical analysis was performed using Statistical Package for the Social Sciences 
software (version 21.0 for Windows; SPSS, Inc, Chicago, Ill). Repeat measure data was 
tested using an independent sample T-test (significance quoted is 2-tailed). 
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CHAPTER 3: RESULTS 1: ACTIVITY AND FUNCTIONS OF RAS 
ISOFORMS 
Hypothesis: no other Ras isoforms are active in pancreatic cancer cells 
 K-RAS CAN BE DEPLETED IN PANCREATIC CANCER CELL LINES. 
Mutant K-Ras is important in the formation of PDAC with evidence suggesting that 
some pancreatic cancer cell lines are addicted to it, and its loss results in cells 
undergoing cell death. (Singh et al., 2009) To identify if this was true for our cell lines, 
K-Ras was depleted using four different Dharmacon siRNAs (Figure 3-1). In all of the 
cell lines tested K-Ras was depleted using two of the four siRNAs (10nmol 48 h post 
transfection) with a third working in MIA PaCa2 and Panc-1 cells. The smart pool 
containing all four siRNAs together was used as a positive control and efficiently 
depleted K-Ras in all of the cell lines. From this data the siRNAs: K-Ras siRNA 1 and 
K-Ras siRNA 3 were the most efficient and worked in all cell lines tested. Therefore, all 
further K-Ras depletion experiments were done using K-Ras siRNA 1 unless otherwise 
stated.  
 K-RAS DEPLETION RESULTS IN VIABLE CELLS AND PROTEIN LEVELS 
WILL RETURN TO NORMAL SEVERAL DAYS AFTER SIRNA TREATMENT 
Suit-2 cells were treated with K-Ras siRNA and grown for several days following 
depletion. They were harvested and cell viability was tested (Figure 3-2). Depletion of 
K-Ras makes little or no difference to cell viability with both the controls and the K-Ras 
depleted cells having cell viabilities above 90%. Additionally, when cells were 
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examined using EdU and PI staining, the population of cells that was shown to be 
apoptotic only increases from 4 % in control to 7.9% in the K-Ras depleted cells (Figure 
3-2). It can be seen in these cells as expected that the loss of K-Ras protein is only a 
transient effect. After 144 h the levels of K-Ras protein have increased and have 
returned to levels similar to the controls after approximately 192 h (Figure 3-3). While 
K-Ras is depleted cell growth is slowed and once K-Ras levels begin to recover the cells 
are able to grow more efficiently. The return of K-Ras to its pre-depletion levels results 
in the cells growing a similar manner to the control cells (Figure 3-4). Therefore we 
observe results that indicate that Suit-2 cells are able to survive the loss of K-Ras and 
continue growing once K-Ras is restored. This suggests that loss of K-Ras does not 
cause any permanent changes that are detrimental to cell growth.    
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: K-Ras depletion in pancreatic cancer cell lines. K-Ras was depleted in 
a) MiaPaCa2; b) Suit-2 and c) Panc-1 using 4 different K-Ras targeting siRNAs. 
K-Ras smart siRNA (all 4 siRNAs in a mixed pool) was used as a positive control 
along with 3 negative controls (no siRNA (Lipofectamine only), non-targeting 
siRNA and RISC free siRNA). K-Ras siRNAs 1, 2 and 3 were effective at depleting 
K-Ras in MIA PaCa2 and Panc-1 but, only 1 and 3 are effective in Suit-2 K-Ras 
siRNA 4 does not appear to be effective at depleting K-Ras in any of the cell lines. 
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: Graphs showing viability of Suit-2 cells. a) K-Ras was depleted and the 
viability of the cells was tested up to 216 h post depletion using a nucleocounter 
(n=1). b) EdU representative FACS analysis showing a small increase in apoptotic 
cells following K-Ras depletion (n=3). c) Table showing average of FACS 
experiments in b) and the range of data measured. 
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: Western blot of Suit-2 cell time course demonstrating the level of K-Ras 
protein up to 216 h post siRNA treatment (n=1).     
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: Cell numbers 48 hours 144 hours and 192 hours following K-Ras depletion (n=1). Cell numbers and viability were calculated using a 
nucleocounter (n=1).  
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 ACTIVE RAS ISOFORMS IN PANCREATIC CANCER CELL LINES 
K-Ras is mutant and is expected to be active in our cell lines. This activity was tested by 
using an active Ras pulldown kit, which used Raf as a substrate to detect Ras activity. 
Once Ras had been pulled down using Raf, we probed using a pan Ras antibody 
supplied in the kit (Figure 3-5). GTP was added to activate Ras (GTP positive control) 
and GDP to give inactive Ras (GDP negative control). The pan Ras antibody detected 
Ras protein in the non-targeting control, with no Ras being detected in the GDP 
negative control and Ras being detected in the GTP positive control. When we looked at 
the K-Ras siRNA treated cells however, the cells that are depleted for K-Ras showed 
Ras to still be present and this band was lost in the same lysate treated with GDP, 
suggesting that the band is active Ras protein. This data not only confirms previous 
observations that other Ras isoforms are present in Suit-2 cells, (Omerovic et al., 2008) 
but also shows evidence suggesting that another Ras isoform is active via Raf.  
 
: Active Ras in Suit-2 cell lines. Active Ras was isolated using Raf from 
Suit-2 cells treated with either K-Ras siRNA or control. For each siRNA one 
sample was pre-treated with GDP negative control, GTP positive control or no 
pre-treatment was applied. A pan Ras antibody from the kit was used to detect the 
presence of Ras protein (n=1).  
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To further examine this I probed Suit-2 cells, which had K-Ras depleted, using 
antibodies against all three Ras isoforms (K, N and H). Looking at total Ras, which 
includes active and inactive forms, it can be seen that all three isoforms are present, 
(Figure 3-6) thus confirming what had previously been reported. Examination of only 
active Ras from our lysates showed that both K-Ras and N-Ras were present but H-Ras 
is not (Figure 3-6). This demonstrates that in the Suit-2 cell line all three Ras isoforms 
are present, but only K and N-Ras are active via Raf. Further examination of BxPC3, 
Panc-1 and a KPC mouse derived cell lines showed that they also contain both K and N-
Ras. The human derived cell lines also have active K and N-Ras, but the KPC derived 
cell line does not appear to have much, if any, active N-Ras activity (Figure 3-7).   
I have demonstrated that human pancreatic cancer cell lines have some N-Ras activity 
but in contrast a cell line, derived from the KPC mouse model, appears to be lacking 
this N-Ras Raf binding activity (Figure 3-7). Additionally it does not appear that N-Ras 
levels are dependent on K-Ras (at least in Suit-2 cells) because depletion of K-Ras 
appears to have no effect on the level of N-Ras protein present (Figure 3-6). 
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: Total and active Ras isoforms in Suit-2 cells. Western blot analysis 
showing the presence of each Ras species, either total Ras or active Ras isolated by 
Raf pulldown. The western blot is representative of the observed results (n=3).  
 
 N-RAS FUNCTIONS IN HUMAN PANCREATIC CANCER CELL LINES 
 RAS ISOFORMS MODIFYING GROWTH PATTERNS 
N-Ras was shown to be active in all three of the human cell lines initially tested (Figure 
3-6 and Figure 3-7), although a derivative of one of the cell lines was later identified 
without this active protein (see below). Using siRNA, N-Ras was depleted alone or in 
conjunction with K-Ras. To determine possible functions for N-Ras, both Ras isoforms 
were depleted and their growth patterns examined using the Seahorse Bioanalyzer 
(Figure 3-8). Mutant K-Ras has previously been demonstrated to be involved in 
reduction of oxidative phosphorylation in cancer cells. (Ying et al., 2012) The loss of K-
Ras results in a shift towards oxidative growth, as shown in Figure 3-8 however, N-Ras 
depletion, does not appear to result in any significant change in the levels of oxidative 
vs non oxidative growth. When both are depleted together an intermediate shift towards 
oxidative growth is observed and this shift is significantly different from both K-Ras 
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depletion alone and the non-targeting control (Figure 3-8). This suggests that N-Ras has 
a function that is the opposite of K-Ras, but its loss alone is not significant to alter the 
levels of oxidative phosphorylation in Suit-2 cells.  
 
: Total and active Ras isoforms in pancreatic cancer cell lines. 
Representative western blot analysis (n=3) to demonstrate the presence or absence 
of total or active Ras isolated by Raf pulldown. The name of each cell line tested is 
given above the blot (n=3). 
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: Effect of K-Ras and N-Ras on oxidative phosphorylation in Suit-2 cells. 
The analysis of the Seahorse Bioanalyzer data shows how the oxygen consumption 
rate (OCR) vs extracellular acidification rate (ECAR) changes with the depletion 
of K-Ras n=7, N-Ras n=5 or both n=5. K-Ras causes the greatest shift towards 
OCR, N-Ras gives little change and K-Ras with N-Ras gives an intermediate result 
when compared to the non-targeting control. 
 
During this project I identified a slower growing Panc-1 cell line with a doubling time 
of approximately 48 hours compared to the normal doubling time of 24hours (defined as 
Panc-1 slow). Both the regular and slow Panc-1 cell lines were obtained from the ATCC 
at different times and both genotyped as Panc-1 cells. Genotyping was done 
independently using the PowerPlex16HS kit and compared to the markers provided by 
the ATCC. Western bolt analysis of Panc-1 slow cells suggests that they do not appear 
to have any active N-Ras present but the faster growing Panc-1 cell line does (Figure 3-
9, Figure 3-7). The growth of these cells was also analysed using the Seahorse 
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Bioanalyzer. Both of the cell lines showed similar patterns of oxidative vs non oxidative 
growth when untreated (Figure 3-10). But when K-Ras was depleted alone in the 
regular Panc-1 cell line it did not appear to result in a change in growth: both K and N-
Ras had to be depleted before a change to oxidative growth was observed (Figure 3-10). 
By contrast the Panc-1 slow cells that did not have active N-Ras demonstrated a similar 
shift towards oxidative growth when K-Ras alone or both K and N Ras were depleted 
(Figure 3-10). This result suggests that N-Ras may have developed a function in these 
cells that is overlapping with that of K-Ras. In the cells where N-Ras is not normally 
active however, K-Ras appears to be capable of maintaining the balance of oxidative vs 
non oxidative growth on its own.  
 
: Active N-Ras presence in two different Panc-1 cell lines.  Two different 
Panc-1 cell lines were tested for active N-Ras (n=1).   
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: Aerobic stress test of two Panc-1 cell lines with different dividing times. Seahorse Bioanalyzer aerobic stress tests to determine the 
ratio of OCR vs ECAR. a) Panc-1 cells (n=1). b) Slow Panc-1 cells (n=1).    
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 RAS ISOFORMS INDEPENDENTLY ALTER CYTOKINE EXPRESSION PATTERNS 
The effect of N-Ras depletion on oxidative phosphorylation is evidence that N-Ras has 
a function in our pancreatic cell lines. This evidence allows us to reject our hypothesis 
that no other Ras isoforms are active but, the impact in this respect does appear small. 
To obtain further evidence related to our original hypothesis and demonstrate functional 
roles for N-Ras in pancreatic cancer cell lines, an impact on the secretions from the cell 
was investigated. These secretions represent a form of finger print for the cell and any 
alteration to this fingerprint would represent a reporter for functional N-Ras activity. To 
examine this, the commercially available Bio-Plex Pro 27 Plex Human Cytokine, 
Chemokine and Growth Factor Assay kit was used. I depleted K-Ras and N-Ras alone 
or in conjunction with each other and the levels of cytokines in the supernatant were 
examined. Of the 27 cytokines that were examined using the assay only five had 
detectable levels in the supernatant Table 11:  these five cytokines were then used to 
analyse the differences between K-Ras and N-Ras. The loss of N-Ras results in a 
relatively higher expression of IL-8 and a lower relative expression of IL-12 (Figure 3-
11). This was not replicated when K-Ras is depleted: IL-12 exhibited an increase 
(Figure 3-11) and the depletion of both N-Ras and K-Ras resulted in a pattern closer to 
K-Ras than N-Ras. This therefore potentially shows a function of N-Ras but its 
significance is unclear.  
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Cytokine Detectable in supernatant (Yes or No) 
PDGF-bb No 
IL-1b No 
IL-1ra No 
IL-2 No 
IL-4 No 
IL-5 No 
IL-6 No 
IL-7 No 
IL-8 Yes 
IL-9 No 
IL-10 Yes 
IL-12 Yes 
IL-13 No 
IL-15 No 
IL-17 No 
Eotaxin No 
FGF basic No 
G-CSF No 
GM-CSF Yes 
IFN-g No 
IP-10 No 
MCP-1(MCAF) No 
MIP-1a No 
MIP-1b No 
RANTES No 
TNF-α No 
VEGF Yes 
Table showing cytokines in the Bio-Plex Pro 27 Plex Human Cytokine, 
Chemokine and Growth Factor Assay kit. All of the cytokines in the Bio-Plex Pro 27 
Plex Human Cytokine assay are listed. The ones highlighted in bold were the ones that 
had detectable levels and were taken for further analysis. 
  
  ROBERT FERGUSON 
 
 100  
 
 
: Effect of K-Ras and N-Ras on the cytokine expression profile of Suit-2 
cells. The graphs show the changes in relative cytokine levels when Suit-2 cells 
were treated with K-Ras, N-Ras or Non-targeting siRNA (n=1). 
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 MEMBRANE LIPID COMPOSITIONS ARE MODIFIED UNIQUELY BY K-RAS AND N-
RAS 
Ras is known to influence membrane composition as described previously, but the exact 
pattern of change will depend on many factors. Suit-2 cells were used to examine how 
the depletion of K-Ras and N-Ras effected the lipid composition of membranes. This 
analysis was carried out on a single sample for each depletion and compared to cells 
treated with non-targeting control siRNA. The loss of K-Ras results in a general 
increase in the more unsaturated phosphatidylcholines (>4 double bonds) and a decrease 
in the less unsaturated ones (<4 double bonds) (Figure 3-12). N-Ras depletion however, 
results in mostly small decreases in abundance with some of the medium length chains 
showing a slight increase (Figure 3-12). The combination treatment results in a pattern 
similar to the K-Ras depletion alone but with smaller changes (Figure 3-12) suggesting 
that N-Ras is perhaps responsible for some small modulation of change in the types of 
phosphatidylcholine present but K-Ras is the effector. 
When phosphatidylethanolamine was examined the general trend when K-Ras was 
depleted was an increase in the levels of the longer chain lipids (most containing more 
than 36 carbons) with the shorter chain moieties decreasing in abundance (Figure 3-13).  
N-Ras depletion shows a similar pattern but once again the level of changes was 
generally smaller (Figure 3-13). Depleting with both K and N-Ras again results in a 
lipid profile that is similar to the K-Ras depletion (Figure 3-13) suggesting again that K-
Ras is the major effector of the phosphatidylethanolamine expression profile.  
K-Ras depletion resulted in a decrease in phosphatidylinositol levels, both in lipids 
containing 2 double bonds or less or more than 7 double bonds (plus the longest chain 
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with 6 double bonds). The lipids with unsaturation levels between these high and low 
points mostly showed increased levels when K-Ras was depleted (Figure 3-14). N-Ras 
depletion did not show any obvious pattern when it was depleted and most of the 
changes in relative abundance were small (Figure 3-14). When both were depleted the 
pattern was similar to that seen with K-Ras. Although, it was noted that the 
phospholipids with 7 double bonds appear to increase in number instead of the large 
decrease seen in the 38 and 40 carbon length chains of the K-Ras depletion (Figure 3-
14).  
Phosphatidylserine demonstrated no obvious pattern with some lipids being increased 
and others being decreased following K-Ras depletion (Figure 3-15). When N-Ras was 
depleted there seems to be more of the phospholipids decreasing in abundance than 
increasing (Figure 3-15). When both were depleted the pattern observed was much 
closer to K-Ras than N-Ras (Figure 3-15).  
Thus, although N-Ras is functionally active in these cells (as shown in Figure 3-6 and 
Figure 3-7) this data indicates that the lipid profile is determined by K-Ras.      
Treating Suit-2 cells with inhibitors of PI3K (GCD-0941) and MAPK (PD0325901) 
changed the relevant abundance of phosphatidylcholine compared to the control. Both 
inhibitors result in an increase in the abundance of the more unsaturated (>4 double 
bonds) although PD0325901 treated cells have a decrease in phosphatidylcholine in 
fatty acid chains with 10 double bonds or greater (Figure 3-16). Depletion of K-Ras 
(Figure 3-12) shows similar patterns of changes in abundance to the cells that were 
treated with either one of the inhibitors. However, the pattern of expression that was 
most similar was when Suit-2 cells were treated with both inhibitors at the same time. 
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This is perhaps surprising as Raf has previously been shown to have little effect on the 
Kennedy pathway (Ramirez de Molina et al., 2002).  
Phosphatidylethanolamine patterns in PD0325901 treated cells (Figure 3-17) were 
stable. However, treatment with GCD-0941 caused an increase in many of the 
phospholipids (Figure 3-17). Combination treatment much more closely resembled 
PI3K inhibition than MAPK (Figure 3-17). K-Ras depletion (Figure 3-13) resembled 
PI3K inhibition although the amount of phosphatidylethanolamines with 2 or 4 double 
bonds appears to change differently. 
PD0325901 treatment results in phosphatidylinositol showing small changes from the 
control (Figure 3-18). GCD-0941 treatment shows greater changes (Figure 3-18) and 
these changes were similar to those observed when both PI3K and MAPK (Figure 3-18) 
were inhibited together or K-Ras alone was depleted (Figure 3-14).  
Finally, phosphatidylserine was examined and once again the individual depletion of 
PI3K closely mirrored both the double drug treatment (Figure 3-19) and the K-Ras 
depletion (Figure 3-15). Therefore, this evidence suggests that the PI3K pathway is 
most likely to be involved in the determination of lipid membrane profiles and is 
perhaps the pathway most closely associated with K-Ras regulation of membrane lipids. 
Other pathways or explanations cannot be excluded however, including changes to cell 
cycle profile.  
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: Membrane lipid analysis of phosphatidylcholine. Relative abundance 
of phosphatidylcholine and phosphatidylcholine species in Suit-2 cells when K-Ras, 
N-Ras or both are depleted compared to non-targeting control siRNA. The dotted 
lines represent groups with the same unsaturation and the chain length increases 
left to right as you move across the group (n=1).    
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: Membrane lipid analysis phosphatidylethanolamine. Relative 
abundance of phosphatidylethanolamine and phosphatidylethanolamine species in 
Suit-2 cells when K-Ras, N-Ras or both are depleted compared to non-targeting 
control siRNA. The dotted lines represent groups with the same unsaturation and 
the chain length increases left to right as you move across the group (n=1).    
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: Membrane lipid analysis phosphatidylinositol. Relative abundance of 
phosphatidylinositol and phosphatidylinositol species in Suit-2 cells when K-Ras, 
N-Ras or both are depleted compared to non-targeting control siRNA. The dotted 
lines represent groups with the same unsaturation and the chain length increases 
left to right as you move across the group (n=1).    
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: Membrane lipid analysis phosphatidylserine. Relative abundance of 
phosphatidylserine and phosphatidylserine species in Suit-2 cells when K-Ras, N-
Ras or both are depleted compared to non-targeting control siRNA. The dotted 
lines represent groups with the same unsaturation and the chain length increases 
left to right as you move across the group (n=1).    
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: Membrane lipid analysis of phosphatidylcholine levels when cells are 
treated with MAPK and PI3K inhibitors. Relative abundance of 
phosphatidylcholine and phosphatidylcholine species in Suit-2 cells when the cells 
are treated with MAPK, PI3K inhibitors either alone or together. The dotted lines 
represent groups with the same unsaturation and the chain length increases left to 
right as you move across the group (n=1).   
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: Membrane lipid analysis of phosphatidylethanolamine levels when 
cells are treated with MAPK and PI3K inhibitors. Relative abundance of 
phosphatidylethanolamine and phosphatidylethanolamine species in Suit-2 cells 
when the cells are treated with MAPK, PI3K inhibitors either alone or together. 
The dotted lines represent groups with the same unsaturation and the chain length 
increases left to right as you move across the group (n=1).   
  
  ROBERT FERGUSON 
 
 110  
 
  
: Membrane lipid analysis of phosphatidylinositol levels when cells are 
treated with MAPK and PI3K inhibitors. Relative abundance of 
phosphatidylinositol and phosphatidylinositol species in Suit-2 cells when the cells 
are treated with MAPK/PI3K inhibitors either alone or together. The dotted lines 
represent groups with the same unsaturation and the chain length increases left to 
right as you move across the group (n=1).   
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: Membrane lipid analysis of phosphatidylserine levels when cells are 
treated with MAPK and PI3K inhibitors. Relative abundance of 
phosphatidylserine and phosphatidylserine species in Suit-2 cells when the cells are 
treated with MAPK/PI3K inhibitors either alone or together. The dotted lines 
represent groups with the same unsaturation and the chain length increases left to 
right as you move across the group (n=1).   
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 SUMMARY 
My hypothesis: no other Ras isoforms apart from K-Ras are active or functional in 
pancreatic cancer cells can be rejected as I demonstrated evidence of N-Ras activity via 
Raf and depletion of N-Ras changed the oxidative vs non oxidative growth profile of 
pancreatic cancer cells when depleted in conjunction with K-Ras. Additionally, I 
demonstrated evidence suggesting that the cytokines IL-8 and IL-12 display changes in 
the levels secreted when N-Ras is depleted. These changes appear to be different to 
those observed when the cells were compared to controls or cells where K-Ras was 
depleted. N-Ras seems to have little effect on the phospholipid profiles of the cells, at 
least in comparison with the impact of K-Ras in these cells. Indicative of the complexity 
of the roles of the different Ras isoforms, acting together and independently although 
further investigation will be required to fully understand the impact of N-Ras on 
phospholipid profiles.  
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RESULTS 2: K-RAS MODULATION OF G2 CYCLINS 
Hypothesis: K-Ras regulates the G2 cyclins via cyclin D. 
 DEPLETING K-RAS BUT NOT N-RAS RESULTS IN A CHANGE IN THE 
EXPRESSION PATTERN OF G2 CYCLINS 
Depleting K-Ras was expected to show a decrease in cyclin D and also a decrease in 
cyclins A and B. (Fleming et al., 2005; Morgan, 2007) If N-Ras was involved in 
controlling the cell cycle then a similar result to K-Ras depletion would be expected. 
When we depleted K-Ras in Suit-2 cells however, little change in the G1 cyclins (D+E) 
and a large decrease in G2 cyclins (A or B) was observed (Figure 3-1. Depletion of N-
Ras did not show a similar pattern and it appears in fact, to have little effect on the 
levels of the cyclins at all. Both K-Ras and N-Ras were depleted (Figure 3-1b) 
indicating that the result was not due to inefficiencies in the siRNA treatment.  
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: Cyclin levels when K or N-Ras were depleted in Suit-2 cells. a) 
Representative western blot showing the levels of cyclins when Suit-2 cells were 
treated with K-Ras or N-Ras siRNA (n=3). b) Western blots demonstrating the 
depletion of K-Ras and N-Ras (n=3). 
 
 EFFECT THAT DEPLETION OF K-RAS AND N-RAS HAS ON OTHER 
TARGETS OF THE APC/C COMPLEX 
The APC/c complex is known to be responsible for targeting the G2 cyclins to the 
proteasome (Peters, 2002). Therefore, it is possible that K-Ras is regulating the APC/c 
complex, and evidence to support this would be seen if other APC/c targets show 
similar patterns of response to the depletion of the different Ras isoforms. Two other 
targets survivin and geminin were tested to see how K-Ras and N-Ras depletion 
effected their levels. N-Ras has little to no effect on the levels of these proteins in a 
similar manner to that observed with the G2 cyclins. K-Ras depletion, however, resulted 
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in a loss of both survivin and geminin in a similar manner to that observed for the G2 
cyclins (Figure 3-2 and Figure 3-1). Therefore, it appears that K-Ras is affecting levels 
of G2 cyclins and this may be caused through its effects on the APC/c complex.  
 
: Levels of proteins targeted by the APC/c after K or N-Ras are depleted. 
Representative western blots showing the levels of two other targets of the APC/c 
complex when K-Ras and N-Ras were depleted using siRNA (n=3).   
 
 FACS ANALYSIS OF SUIT-2 CELLS WHEN K-RAS IS DEPLETED.  
 PROPIDIUM IODIDE ANALYSIS 
One possible explanation for the results observed with the G2 cyclins and other APC/c 
targets would be that G2 cells are being lost. If the G2 cell population was significantly 
decreased then a drop in these different G2 proteins would be expected. Therefore, 
FACS analysis was done to see if there was a reduction in G2 cells.  
The FACS analysis showed that when K-Ras was depleted there was little change in the 
G2 peak, but a reduction in S-phase was observed (Figure 3-3). This indicates that K-
  ROBERT FERGUSON 
 
 116  
 
Ras depletion was not causing G2 cells to be lost in greater numbers and therefore is 
unlikely to explain the change in G2 cyclin levels (Figure 3-1).  
 
: FACS analysis following K-Ras depletion. Representative FACS 
analysis of the cell cycle using PI staining demonstrating a decrease in S-phase but 
little change in the G2 cell population. a) Non-targeting siRNA treated cells (n=3); 
b) K-Ras depleted Suit-2 cells (n=3) 
 
 EDU FACS ANALYSIS 
Further analysis of the cell cycle was done in Suit-2 cells using 5-ethynyl-2’-
deoxiuridine (EdU) to examine if cells continue to progress through S-phase and if the 
number of cells in G2 is changing after K-Ras depletion. EdU incorporates in DNA 
when it is being replicated in S-phase. Any cell that has passed through S-phase after 
the addition of EdU will be labelled. Using this we can determine the cell cycle fate of 
cells that pass through S-phase. K-Ras depletion results in an increase in the proportion 
of cells that are unlabelled G2 cell population (Figure 3-4). In order for these cells to be 
unlabelled in G2 they must have been present in G2 since labelling began. This 
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demonstrates that K-Ras depletion far from forcing cells out of G2, actually causes a 
relative increase in a subpopulation of cells which started in G2 and have not left.   
 
: EdU cell cycle analysis of K-Ras depleted Suit-2 cells. An example of 
EdU analysis of the cell cycle showing that the proportion of unlabelled G2 cells 
increases following the depletion of K-Ras. a) Non-targeting control treated cells, 
b) K-Ras depleted cells, c) Table showing relative % distribution of cells in cell 
cycle phases.  
  
The effect of the period of exposure to EdU was analysed. When K-Ras was depleted, 
the unlabelled population of G2 cells relative to the total number of G2 cells decreased 
with increasing time of EdU exposure; suggesting cells were slowly moving from G2 
into G1 (Figure 3-5). When there was no K-Ras depletion however, there was a constant 
proportion of cells in G2 that did not change; suggesting that cells are entering and 
leaving G2 at a similar rate; the constant level of unlabelled cells represent a non-
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cycling population. The level of unlabelled G2 cells after K-Ras depletion decreases 
towards the constant level of non-cycling cells seen with no K-Ras depletion. When 
examining the number of unlabelled cells in G2 as a proportion of the total number of 
unlabelled cells, it is expected that a decrease would be seen as the cells cycle from G2 
to G1 (being replaced by labelled cells in G2). This was seen with cells treated with 
control siRNA but not in cells with K-Ras depletion (Figure 3-5). Suggesting that after 
K-Ras depletion cells must be leaving G1 at approximately three times the rate that they 
are leaving G2 (1 cell leaving G2 + 2 entering G1 due to cell division= change of 3cells 
in total). This data suggests that K-Ras depletion is in fact slowing the loss of cells from 
G2 rather than promoting it. Together, the FACS data shown suggests that loss of G2 
cells does not explain the decrease in G2 cyclins when K-Ras is depleted and therefore, 
K-Ras must promote their upregulation by another manner. 
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: Analysis of EdU labelling over time. a) Comparison of changes to the 
proportion of G2 unlabelled cells vs total G2 over increasing periods of exposure to 
Edu when K-Ras is depleted (n=2). b) Comparison of the change in the proportion 
of G2 unlabelled cells vs total number of unlabelled cells over increasing periods of 
exposure to Edu when K-Ras is depleted (n=2). c) A 3rd repeat has been done and 
gave the same trend but due to lack of synchronisation the time points were too far 
offset to allow data to be included in an average for each point, % of unlabelled in 
G2 for repeats 1, 2 and 3 are shown, notice that 22 hour time point for 1 and 2 are 
equivalent to 18 hours for 3.   
 
 IS MAPK OR PI3K/AKT SIGNALLING RESPONSIBLE FOR DEPLETION OF 
CYCLINS? 
K-Ras functions through many signalling pathways, but two of the most common ones 
are the MAPK pathway and the PI3K/Akt pathways. In order to determine if either one 
of these pathways were involved in controlling the levels of G2 cyclins I used the MEK 
inhibitor PD0325901 and the PI3K inhibitor GDC-0941. Cells that were treated with K-
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Ras siRNA or control siRNA were given these inhibitors 24 hours post siRNA 
treatment and were then left for a further 24 hours before harvesting. If K-Ras is 
controlling the cells through either of these pathways, inhibition of the pathway would 
cause control and K-Ras siRNA treated cells to look similar. Treatment with control 
siRNA followed by inhibitor treatment did not cause protein levels of the G2 cyclins to 
look similar to when they are treated with K-Ras siRNA (Figure 3-6 compared to Figure 
3-1). Treatment with these inhibitors did not appear to demonstrate an effect on cyclin 
D or cyclin E either. Cyclin D and cyclin E showed little change in protein levels when 
K-Ras was depleted (Figure 3-1) and the addition of the inhibitors had little or no effect 
on the expression pattern of the protein (Figure 3-6).  
Inhibition of MAPK or Akt signalling alone does not appear to be effective in 
eliminating the difference between cells treated with K-Ras siRNA and control siRNA. 
Therefore, I repeated the experiment and added both drugs concurrently 24 hours after 
siRNA treatment. This was done to examine if this inhibition of both pathways 
simultaneously could eliminate the differences in G2 cyclins between the control and K-
Ras depleted cells. The addition of both drugs results in no detectable level of cyclin A 
with either siRNA treatment and the levels of cyclin B are decreased to similar levels in 
both the control and K-Ras depleted cells (Figure 3-7). Therefore, it appears that loss of 
both MAPK and Akt signalling pathways can result in the loss of G2 cyclins. This 
coupled with the fact that each one individually is unable to alter the protein levels of 
the G2 cyclins suggests that cross talk between the pathways is able to overcome the 
loss of signalling from one of them alone. It is also possible that this result is not the 
reason for the changes observed in G2 cyclins when K-Ras is depleted, but rather, it is 
due to another set of signals that when lost may result in the loss of G2 cyclins 
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independently of K-Ras. Treatment of Suit-2 with both drugs also results in decreased 
levels of G1 cyclins and the overall pattern was the same with either siRNA (Figure 3-
7). 
 
: Effect of MAPK and Akt inhibitors on cyclin levels when K-Ras is 
depleted. Representative western blot showing changes in cyclins levels when (a) 
Akt (GDC-0941)  and (b)MAPK (PD0325901) are inhibited and cells are treated 
with K-Ras or control siRNA (n=3). 
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: Effect of combined treatment of MAPK and Akt inhibitors on cyclin 
levels when K-Ras is depleted. Western blot showing changes in cyclins levels when 
Akt (GDC-0941) and MAPK (PD0325901) are inhibited with or without K-Ras 
depletion. The addition of both drugs results in almost complete loss of both cyclin 
A and cyclin B. Cyclin D and E also have decreased levels. These effects are 
independent of K-Ras depletion. a) cyclin A blot, b) cyclin B blot, c) cyclin D blot, 
d) cyclin E blot (n=3). 
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 FACS TIME COURSE COMPARING K-RAS AND CYCLIN D KNOCKDOWNS 
K-Ras is thought to function through cyclin D to push cells through S-phase into G2. 
My inhibitor data suggests that this may not be the case in Suit-2 cells. If K-Ras 
functions through cyclin D it would be expected to show a similar pattern of decreasing 
G2 cells when either cyclin D or K-Ras is depleted.  In a single experiment using Suit-2 
cells, when I depleted cyclin D and measured the cell cycle at both 48 hours and 72 
hours post depletion, there were approximately 10% G2 cells at both time points. When 
I looked at K-Ras depletion it can be seen that there is approximately 10% G2 cells after 
48 hours but it had risen to 18% after 72 hours (Figure 3-8a+b). Western blot analysis 
of the G2 cyclins shows that they are decreased after both treatments and comparison 
between K-Ras and cyclin D depletion would suggest that the G2 cyclins are lower after 
loss of K-Ras. Therefore, this data is further evidence suggesting that K-Ras is unlikely 
to be acting exclusively through cyclin D in Suit-2 cells.  
 POTENTIAL INTERMEDIATES BETWEEN K-RAS AND THE G2 CYCLINS 
 AMPK 
K-Ras does not appear to be interacting with the G2 cyclins exclusively via cyclin D, 
therefore, there is likely to be some other mechanism to facilitate its control of the G2 
cyclins. One possibility could be that K-Ras is regulating AMPK. Phosphorylation of 
AMPK results in its activation, therefore if K-Ras is activating AMPK I would expect to 
see a decrease in phosphoAMPK when it is depleted. This would also be an alternative 
explanation linking K-Ras and changes in lipid profile (via mitotic exit checkpoint 
regulation).  K-Ras was depleted and phosphoAMPK levels were examined in both 
Suit-2 and MIA PaCa2 cells. The depletion of K-Ras using either K-Ras siRNA 1 or 3 
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did not change the levels of phosphoAMPK. This indicates that AMPK is unlikely to be 
the intermediate as K-Ras does not appear to alter its activation, and it would therefore 
be unable to mediate a change in G2 cyclin levels in response to the gain or loss of K-
Ras.  
 
  ROBERT FERGUSON 
 
 125  
 
 
: Comparison of the effects of both K-Ras and cyclin D depletion on the 
cell cycle and G2 cyclins. a) PI plot of cell cycle 48 h b) or 72 h after K-Ras or 
cyclin D depletion showing how they affect the presence of cells in G1 or G2. c) 
Western blot showing the levels of G2 cyclins 48 h or 72 h post K-Ras or cyclin D 
depletion (n=1). 
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: PhosphoAMPK and how its levels change in response to K-Ras 
depletion. PhosphoAMPK levels in response to K-Ras depletion were looked at in 
Suit-2 and MIA PaCa2 cells (n=1). 
 
 RAL A AND RAL B 
It has previously been shown that Rals are able to alter the level of survivin in response 
to K-Ras. (Tecleab and Sebti, 2013) Therefore, I wished to investigate if this was also 
the cause of the changes in G2 cyclins because previously I had demonstrated that 
depletion of K-Ras, resulted in a similar decrease in both survivin (Figure 3-2) and the 
G2 cyclins (Figure 3-1). RalA and RalB were depleted independently and in 
conjunction with each other with the effect on the G2 cyclins being examined. The loss 
of either Ral, or both together based on a single experiment had little effect on the level 
of the G2 proteins (Figure 3-10). Therefore this suggests that K-Ras is not controlling 
the levels of G2 cyclins via the RalGDS pathway. 
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: Depletion of Rals and its effect the levels of G2 cyclins. Ral A or B 
were depleted either independently or in conjunction with each other and their 
effect on G2 cyclins was measured (n=1). 
 
 BORTEZOMIB TREATMENT OF K-RAS DEPLETED CELLS 
Bortezomib treatment results in the inhibition of the proteasome and therefore any 
proteins targeted to the proteasome via the APC/c complex will not be degraded. K-Ras 
depleted cells were treated with bortezomib and the level of cyclin B was measured 
(Figure 3-11).  The addition of K-Ras siRNA degradation of cyclin B as previously 
demonstrated (Figure 3-1). The addition of bortezomib appears to counter this effect 
because when K-Ras was depleted, and the cells were treated with bortezomib, the 
levels of cyclin B do not decrease. 
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To further show this I repeated the treatment as above, but used an ubiquitin pull-down 
kit to specifically isolate only proteins that have been tagged by ubiquitin. When I did 
the western blot of this, a similar recovery of G2 cyclins following bortezomib 
treatment was expected. However, bortezomib with K-Ras depletion appears to cause a 
decrease in ubiquitinated cyclin B compared to K-Ras depletion alone. Cyclin D 
depletion followed by bortezomib treatment shows the expected recovery of cyclin B 
protein (Figure 3-11). If K-Ras increased G2 cyclins by inhibiting the APC/c complex 
the proteasome inhibitor would result in increased cyclin B levels. The decrease in total 
cyclin B (Figure 3-11a) suggests that whatever the mechanism by which K-Ras is 
controlling the levels of G2 cyclins it involves degradation of an intermediate protein 
via the proteasome. This is further evidence that K-Ras is not functioning through 
cyclin D because the bortezomib treatment effects the depletion of either K-Ras or 
cyclin D differently (Figure 3-11). 
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: K-Ras dependent increase in G2 cyclin level is not the result of 
blocking proteolysis of ubiquitinated cyclins a) Representative western blots 
showing the effect of K-Ras depletion on total cyclin B in and how bortezomib 
treatment alters the effect Suit-2 cells (n=3) Panc-1(n=1) b) Representative western 
blot showing the effect of bortezomib and siRNA in combination Suit-2 cells (n=3). 
c) Densitometry scan of westerns represented in b (n=3).  K-Ras depletion does not 
significantly decrease ubiquitinated cyclin B. K-Ras depletion in the presence of 
bortezomib decreases the level of ubiquitinated cyclin B.  
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 FACS ANALYSIS AND WESTERN BLOTS TO DETERMINE IF G2 CYCLINS 
ARE PRESENT IN G1 
If K-Ras is not effecting the levels of G2 cyclins via the APC/c complex it is possible 
that the G2 cyclins are no longer limited to G2. To test this I looked at Suit-2 cells as 
they become confluent. When they are growing less/slower, more cells will be in found 
in G1/0 than in G2 compared to when they are in an exponential growth phase. 
(Kuppers et al., 2010) Therefore Suit-2 cells were grown to confluence to decrease the 
number of cells that were in G2. After 96 hours it was found that most of the cells were 
in G1 (75.8% at 96 hours compared to 67.7% after 72 hours) with the G2 peak having 
decreased to just 4.0% of the total cell population from 14.4% at 72 hours (Figure 3-12). 
When the G2 cyclins were examined by western blot there was little change. This 
suggests in conjunction with Figure 3-8, that not only is K-Ras affecting the cells in a 
manner that is not the same as the classically considered cyclin D pathway, but that the 
G2 cyclins are possibly produced in cells outside of G2.      
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: Analysis to determine the presence of G2 cyclins in cells 
predominately in G1 phase cells. a) PI plot of cells at 72 h and 96 h (n=1) b) 
Western blot probed for cyclin A and cyclin B to examine how the G2 cyclin levels 
were affected when most of the cells were in G1 (n=1). 
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 TRANSCRIPTIONAL ANALYSIS OF G2 CYCLINS WHEN K-RAS IS DEPLETED 
G2 cyclins do not appear to be restricted to G2 or controlled via the APC/c complex by 
K-Ras. Therefore I used Quantitative Reverse Transcriptase Real Time PCR (qRT-
PCR) to assess if the regulation of the G2 cyclins is at the transcriptional level. 
Depletion of K-Ras results in a significant decrease in cyclin B transcript levels and a 
much smaller decrease in cyclin A (Figure 3-13). The loss of cyclin D also results in a 
decrease of the G2 cyclins. K-Ras depletion causes a much greater loss of cyclin B 
transcripts than cyclin D depletion. This provides further evidence that K-Ras is 
controlling cyclin B in an independent manner to cyclin D, and that the control of cyclin 
B at least is via transcriptional regulation. The low level of the reduction in cyclin A 
transcripts (roughly equivalent to that seen after cyclin D depletion) does not eliminate 
the possibility that it is of biological significance. 
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: Effect of depleting K-Ras (cyclin A n=4, cyclin B n=5) or cyclin D 
(cyclin A n=3, cyclin B n=4) on G2 cyclin transcript levels. Graph showing the 
decrease in G2 cyclin levels following K-Ras or cyclin D depletion.  
 
 EFFECT OF BORTEZOMIB ON THE LEVELS OF G2 CYCLIN TRANSCRIPTS 
WHEN K-RAS IS DEPLETED 
There is evidence that the depletion of K-Ras results in a decrease in G2 cyclin 
transcripts (Figure 3-13). When the cells were also treated with bortezomib, an increase 
in cyclin B transcript levels and a decrease in the transcription levels of cyclin A (Figure 
3-14) was observed, suggesting that bortezomib can recover some of the loss in cyclin B 
transcription following K-Ras depletion. The treatment with bortezomib alone with 
control siRNA demonstrated an increase in the transcription levels of both cyclin A and 
B (Figure 3-14).  
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: Effects on G2 cyclins when Suit-2 cells are treated with K-Ras siRNA 
and bortezomib. Graph showing the effect when Suit-2 cells were treated with K-
Ras siRNA of Non-targeting siRNA and then bortezomib 24 h later. (n=1).  
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 SUMMARY 
My hypothesis for this work was that K-Ras only regulates the G2 cyclins via cyclin D 
in a cell dependent manner. This hypothesis can be rejected as depletion of K-Ras 
causes a depletion of G2 cyclins without a simultaneous decrease in cyclin D and does 
not cause a G1 arrest. K-Ras depletion in fact is demonstrated to cause a slowing of 
cells exiting from G2 and is likely to be causing a slowing of the cell cycle in general. 
The hypothesis was rejected and the APC/c was examined to determine if it was 
responsible for the loss of G2 cyclins. Inhibition of the proteasome was not able to 
recover the loss of ubiquitinated cyclin B.  K-Ras depletion in the presence of 
Bortezomib results in a decrease in the level of ubiquitinated cyclin B. The transcription 
of the G2 cyclins was examined and the levels of cyclin B transcript decreased more 
when K-Ras was depleted, than when cyclin D was depleted. Therefore, I have provided 
evidence that K-Ras is able to modulate the levels of G2 cyclins in a manner that is 
independent of the cell cycle and cyclin D. For cyclin B this regulation appears to be 
transcriptional. 
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CHAPTER 4: DISCUSSION 
 K-RAS DEPLETION RESULTS IN VIABLE CELLS 
Objectives of this thesis were to identify if Ras isoforms other than K-Ras are active in 
pancreatic cancer cells and if they have any functions that differ to K-Ras, then to 
examine how active Ras isoforms modulate cyclin levels in PDAC cell lines, and 
identify if cyclin regulation extends beyond the classical paradigm described for cyclin 
D.  I had two hypothesis based on the literature; that no other Ras isoforms are active or 
functional in pancreatic cancer cells and that K-Ras only regulates the G2 cyclins via 
cyclin D in a cell cycle dependent manner. 
The objectives of this thesis relate to K-Ras dependency, so I first set out to confirm and 
further elucidate the effects that K-Ras has on specific pancreatic cancer cells. K-Ras 
depletion using siRNA (as demonstrated by western blot) in Suit-2, MIA PaCa 2 and 
Panc-1 cells was well tolerated (Figure 3-1), although it gave a relative reduction in cell 
growth when compared to controls. Singh et al have previously defined Panc-1 cells as 
independent of K-Ras depletion in agreement with the results that I have observed. 
(Singh et al., 2009) The Ras dependency state of Suit-2 cells in their analysis was in 
contradiction to their own hypothesis because their panel of genes for determining 
dependence classified Suit-2 as independent. (Singh et al., 2009) When they examined 
cell density following K-Ras depletion however, they concluded that they were in fact, 
dependent. (Singh et al., 2009) The genetic markers that were discovered by Singh et al, 
represented genes involved in epithelial differentiation and cell survival with several 
being involved in the apoptosis pathway. (Singh et al., 2009)  I would argue that Singh 
et al correctly classified Suit-2 cells as independent based on their model and 
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incorrectly classified the line as dependent, due to their definition of dependency was 
empirically based on cell density (growth) rather than cell death. When I examined Suit-
2 cells for evidence of cell death I found that the cells had similar levels of viability 
when treated with K-Ras or control siRNA (>90%), and that K-Ras depletion only 
resulted in a 6.7% increase in apoptotic cells (4.5% to 11.1%) (Figure 3-2). This 
therefore, suggests that the loss in cell density observed by Singh et al, in Suit 2 cells is 
likely to be due to a lack of cell growth. When the growth of Suit-2 was tracked while 
K-Ras was depleted, it is noticeable that there was an increase in cell growth following 
the restoration of K-Ras protein levels (Figure 3-3 and Figure 3-4). This provides 
further evidence that Suit-2 cells are dependent on K-Ras for growth rather than 
survival. Supporting this, cells surviving the loss of K-Ras by entering a slowed period 
of growth have been shown in mouse models: (Viale et al., 2014) the loss of K-Ras 
leaves small surviving cell (SC) populations in a slowed growth state. Once K-Ras 
returns to its higher, pre-depletion levels, tumours can rapidly form. (Viale et al., 2014) 
 ACTIVE RAS ISOFORMS IN PANCREATIC CANCER CELLS 
K-Ras is the only mutated isoform that is commonly seen in pancreatic cancer (Biankin 
et al., 2012) and therefore is commonly thought of as the being the Ras isoform that is 
the key controller of downstream signalling. Recently there has been some evidence to 
show that the other Ras isoforms are also present in pancreatic cancer cells, (Omerovic 
et al., 2008) as well as some basic evidence for a possible function. (Young et al., 2013) 
Western blot analysis confirmed the presence of N-Ras in Suit-2 (Figure 3-6), Panc-1, 
BxPC3 cells and a cell line that had been isolated from a KPC mouse (Figure 3-7). In 
addition I isolated both active K-Ras and N-Ras in our human cell lines but not our 
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KPC mouse cell line (Figure 3-6+Figure 3-7). This demonstrates, in agreement with 
Young et al, (Young et al., 2013) that N-Ras is not just present in human pancreatic 
cancer cell lines but it is capable of promoting signalling at least via Raf. It also 
suggests that, while an invaluable model, the artificial genesis of the KPC mouse may 
result in it having different characteristics to, at least, some human pancreatic cancers.  
Others have already demonstrated K-Ras has an important role in cell proliferation and 
growth as well as cell survival. (Singh et al., 2009)  Since I have shown N-Ras is active 
in our pancreatic cancer cell lines, I wanted to determine if N-Ras was able to function 
(independently or with K-Ras) in controlling various different facets of cell biology. 
The Seahorse Bioanalyzer allows the measurement of the growth response of cells to 
the depletion of K or N-Ras alone or together. I examined the change in the 
OCR/ECAR levels (the ratio of respiratory growth to non-respiratory growth) when 
depleting one or both Ras isoforms in our Suit-2 cells (Figure 3-8). When I did this I 
saw little difference when N-Ras was depleted compared to the control and a large 
movement toward respiratory growth when K-Ras was depleted: which is consistent 
with previous reports.(Ying et al., 2012) When both were depleted simultaneously an 
intermediate level of OCR/ECAR was observed, it was significantly different from the 
K-Ras depleted cells or cells treated with control siRNA. N-Ras appears to have a 
function that is in opposition to that of K-Ras. The loss of N-Ras alone however, shows 
no significant change in OCR/ECAR, suggesting that K-Ras is the dominant isoform in 
determining the levels of respiratory vs non-respiratory growth.   
I identified two different strains of the Panc-1 cell line that have different doubling 
times and when they were examined for N-Ras it was only present in the strain with the 
faster growth (Figure 3-9). These two different strains were then examined using the 
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Seahorse Bioanalyzer (Figure 3-10) and it was found that N-Ras depletion had no effect 
on the slower growing strain (unsurprising as it did not contain any substantial active N-
Ras protein before depletion). In contrast to the Suit-2 cells, N-Ras appears to have an 
effect in the faster growing Panc-1 cells. Here K-Ras depletion alone changes the 
OCR/ECAR ratio very little compared to control treated cells. The depletion of both K 
and N-Ras results in a movement towards respiratory growth; noticeably similar to 
OCR/ECAR in the K-Ras depleted slow growing Panc-1 cell line. Although the role of 
mutant K-Ras in regulating oxidative phosphorylation has been described previously, 
(Ying et al., 2012) the role of wild type N-Ras in these cells has not previously been 
examined. The importance of N-Ras relative to K-Ras appears to vary according to the 
cell line, with K-Ras masking any effect in Suit-2, but in the normal Panc-1 cell line N-
Ras appears to have an important role in the maintenance of non-respiratory growth. 
Examination of a 27plex of cytokines also provided evidence that N-Ras has a 
functional impact on the cell. From the panel of 24 cytokines only 5 had levels that were 
detectable in the assay (Table 11: . Of these I observed obvious changes in two of these 
cytokines when comparing the depletion of N-Ras or K-Ras to each other or the control. 
Depleting N-Ras results in a small decrease in the levels of IL-12 compared to the 
control (Figure 3-11) and an increase is observed when K-Ras is depleted. IL-12 has 
been previously reported to be downregulated by PI3K signalling in antigen presenting 
cells where it is involved in stimulating the immune response.(Fukao et al., 2002) I 
would hypothesise that the mutant K-Ras is involved in the reduction of IL-12, which 
potentially may help the tumour remain hidden from the immune system. Perhaps N-
Ras is functioning through another pathway (perhaps MAPK) and therefore, its loss 
results in a decrease in IL-12. 
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IL-8 has previously been shown to be a transcriptional target of the Ras signalling 
pathway and has been found to be important in the induction of tumour growth in cells 
with mutant Ras. (Yasumoto et al., 1992) The depletion of K-Ras has little effect on the 
level of IL-8 relative to the other cytokines, whereas the depletion of N-Ras results in an 
increase in the relative levels of IL-8 being secreted from the cell (Figure 3-11). The 
loss of both isoforms shows little change in the relative level of IL-8 when compared to 
the control. Based on this data, and what has been previously demonstrated, it is 
possible to hypothesize that N-Ras has a negative regulatory function of IL-8, and K-
Ras is involved in promoting its production; possibly via the previously demonstrated 
transcriptional control mechanism. (Yasumoto et al., 1992) 
When I looked at the lipid profiles of our cells, K-Ras appeared to be the dominant 
isoform in determining the profiles. On the basis that the change in profile appears 
somewhat similar when PI3K or K-Ras is targeted. I would hypothesise that K-Ras may 
be acting in this respect through the PI3K pathway rather than MAPK pathway (Figure 
3-12 to Figure 3-19).  
Wild type N-Ras appears to have some functions unique to it. I have also shown 
evidence where K-Ras appears to be the dominant Ras isoform. In these cases the loss 
of N-Ras has only a minor impact but that concurrent depletion of K-Ras and N-Ras 
results in an effect distinct from depletion of K-Ras alone is depleted. I can conclude 
that N-Ras is active and has functional roles in pancreatic cancer, and therefore reject 
the hypothesis that no other Ras isoforms are active or functional in pancreatic cancer 
cells.   
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 EFFECTS OF RAS ON THE CYCLINS 
As previously mentioned, K-Ras can promote the upregulation of cyclins and so 
activation of key Cdks promoting the cell cycle. Previous work has suggested that K-
Ras mainly functions through cyclin D, (Bretones et al., 2014) but this thesis 
demonstrates little change in cyclin D levels and much larger changes in cyclins A and 
B (Figure 3-1). Both cyclin A and cyclin B are degraded via the APC/c and therefore, I 
examined the effect that depletion of K-Ras and N-Ras had on two other targets of the 
APC/c (survivin and geminin) (Figure 3-2). Both of these alternate targets showed 
results similar to those seen with cyclin A and B. This initially led me to believe that 
control of the levels of G2 cyclins by K-Ras was at the degradation level by control of 
the proteasome. This was supported by PI FACS analysis of the K-Ras depleted cells, 
where a G2 fraction was still observed (Figure 3-3). Others have shown that cyclin D 
loss causes a G1 arrest (Masamha and Benbrook, 2009) and the PI FACS analysis 
comparison of K-Ras depleted cells vs cyclin D, confirmed the expected cyclin D result 
in contrast to the result with K-Ras depletion (Figure 3-8). Therefore, the hypothesis 
that a loss of G2 cells explains the decrease in G2 cyclins can be rejected.  
To further examine the growth patterns of Suit-2 and to elucidate how proliferation of 
the cells has decreased either by arrest or slowing of the cell cycle, cells entering S-
phase were labelled using EdU (Figure 3-4). This experiment demonstrated that K-Ras 
depletion slows exit from G2, rather than promoting it. Comparison of the G2 
unlabelled cells vs the total unlabelled cells suggested that K-Ras depleted cells must be 
leaving G1, approximately 3 times faster than they enter G2 (Figure 3-5).  This would 
add further to my previous postulation that Suit-2 cells are dependent on K-Ras for 
growth but not survival. It also provides additional evidence that the changes in the G2 
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cyclins observed in my western blot analysis are not just side effects of a change in the 
cell cycle profile. 
K-Ras has been shown to function through both the MAPK and PI3K pathways (De 
Luca et al., 2012). To determine if the change in G2 cyclins is caused via either 
signalling pathway I used inhibitors specific to each. Inhibition of each pathway on its 
own failed to demonstrate the same decrease in expression of G2 cyclins seen with K-
Ras depletion (Figure 3-6). When both pathways were inhibited the G2 cyclins were 
decreased. This decrease was greater than the K-Ras depletion alone and double 
inhibitor treatment demonstrated a greater decrease in cyclin D than when K-Ras is 
depleted (Figure 3-7). Therefore, it is possible to suggest that G2 cyclin expression 
requires both pathways, and that the intercommunication between the pathways, make 
the inhibition of one insufficient to replicate the effects seen by K-Ras depletion. 
Alternatively, when both pathways are blocked loss of G2 and G1 cyclins may be due to 
a different mechanism than the loss of G2 cyclins with K-Ras depletion. 
I have determined that the K-Ras specific effect on G2 cyclins is not solely down to the 
cell cycle. In addition I have shown two other targets of the APC/c (survivin and 
geminin) respond to the loss of K-Ras in a similar manner. I wished to investigate 
whether the levels of G2 cyclins were controlled by the APC/c complex and to do this I 
inhibited the proteasome using bortezomib. Inhibition of the proteasome will lead to an 
increase in ubiquitinated proteins as they are not being destroyed. (Hershko and 
Ciechanover, 1998) If G2 cyclins levels are controlled via the APC/c then the inhibition 
of the proteasome should rescue the loss of G2 cyclins following K-Ras depletion. 
Bortezomib treatment of cells did rescue the loss of the G2 cyclins (Figure 3-11). To 
confirm the direct role of an E3 ligase on G2 cyclins, (consistent with APC/c regulation 
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by K-Ras) I looked at the ubiquitinated G2 cyclins specifically. Following K-Ras 
depletion and bortezomib treatment ubiquitinated G2 cyclin levels decreased (Figure 3-
11). This suggests that G2 cyclins levels are not being controlled via their targeted 
degradation via APC/c. However, G2 cyclin regulation must involve some form of 
proteasome mediated degradation, either upstream or downstream of K-Ras, because it 
is affected by bortezomib. Testing of cyclin D under the same conditions showed that 
any decrease in the level of cyclin D was recovered when the cells were also treated 
with bortezomib (Figure 3-11), providing further strong evidence that the K-Ras effect 
on G2 cyclins is not via cyclin D.  
G2 cyclins, as the name suggests, are present in normal cells when they are in G2. 
However, when cells were concentrated in G1 (by growing them to confluence), I 
observed little change in the levels of the G2 cyclins (Figure 3-12). This suggests that in 
Suit-2 cells G2 cyclins are not just restricted to G2.  
A previous study had demonstrated Ral A and Ral B to be targets for K-Ras mediated 
regulation of survivin in lung cancer cells. (Tecleab and Sebti, 2013) In this thesis I 
showed that depletion of Ral A and Ral B alone or in conjunction with each other, did 
not change the levels of the G2 cyclins in Suit-2. Thus it can be concluded that K-Ras is 
not functioning through this pathway to control the levels of the G2 cyclins.  
I also found that when K-Ras was depleted, the level of cyclin B transcripts decreased 
several fold (cyclin A was effected much less) and concluded that K-Ras is controlling 
the levels of cyclin B, at least transcriptionally (Figure 3-13). This leads towards a 
model (Figure 4-1) whereby there is an unknown K-Ras regulated protein or proteins 
involved in activating transcription of G2 cyclins; this will be described below as 
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protein X. This protein is normally degraded via the proteasome but mutant K-Ras 
either directly or indirectly is involved in stabilising it.  The depletion of K-Ras results 
in the degradation of protein X and therefore a decrease in the transcription of G2 
cyclins (at least cyclin B). The addition of bortezomib stabilises protein X resulting in 
rescue of G2 cyclins from K-Ras depletion. Bortezomib has also been shown to stop 
cells entering G2. (Baiz et al., 2009) Treatment of our cells with bortezomib shows a 
decrease in ubiquitinated G2 cyclins (Figure 3-11). Which is likely because they remain 
in G1 where the APC/c mitotic complex is not active and able to ubiquitinate them. 
Initial data examining transcripts of cells treated with bortezomib compared to those 
without suggests that the treatment, results in a decrease in the number of cyclin B 
transcripts and an increase in cyclin A transcripts when K-Ras is depleted (Figure 3-14). 
Also it is notable that there appears to be a general increase in transcription of G2 
cyclins when control cells are treated with bortezomib.  
I have provided evidence that K-Ras controls the G2 cyclins transcriptionally through a 
novel, and as of yet undefined pathway which is not reliant on cyclin D. Therefore I can 
reject the hypothesis that I presented initially, that K-Ras only regulates the G2 cyclins 
via cyclin D in a cell cycle dependent manner.  
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: Model suggesting a mechanism to explain non cell cycle dependent G2 
cyclin levels. (1) Mutant K-Ras depletion causes a reduction in the transcription of 
G2 cyclins (at least B1), which is inhibited by bortezomib, suggesting the 
oncoprotein inhibits proteasomal degradation of a protein(s) described here as 
protein x.  (2) Wild-type (or mutant) Ras will increase transcription of G2 cyclins 
via G1 cyclins in a cell cycle dependent fashion. EGFR will activate this process 
but can also increase G1 cyclins by directly binding to their promoters. (3) G2 
cyclins will be degraded via the APC/c complex and so in the absence of mutant 
Ras the level of the G2 cyclins will be limited by the proportion of cells in G2. (4) 
Bortezomib will inhibit the proteasome causing stabilisation of ubiquitinated G2 
cyclins, but will reduce the production of ubiquitinated protein by restricting entry 
to (and so exit from) G2. 
 
 FUTURE WORK 
This work has been done mainly in the Suit-2 cell line, although I have also 
demonstrated functional N-Ras in other cell lines. The next step would be to examine 
primary cell lines to see if they show the presence of active N-Ras. If this was 
demonstrated to be true then I would then proceed to Luminex and Seahorse analysis to 
see if these cells demonstrate similar characteristics to those observed in Suit-2 cells.  
I also did a prelimary study on the lipid profiles of cells with various Ras isoforms 
depleted. I saw that K-Ras depletions caused changes in these profiles, I would like to 
examine the difference between tumour and normal tissues of the same patient when the 
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mutation status of K-Ras is known. This can be done with our collaborators using 
primary cells isolated from the tumours or directly from the tissue itself. 
A model has been proposed involving an undefined protein/ pathway (protein X) that is 
responsible for the direct control of G2 cyclins transcript levels. I would like to perform 
further analysis of cells treated with K-Ras +/- bortezomib vs control siRNA treated 
cells +/- bortezomib. Microarray analysis comparing the different conditions would help 
to isolate proteins that are changing levels in response to the different treatments. The 
identified proteins could then be depleted or overexpressed to see if the pattern of G2 
cyclins were altered consistent with the model. A yeast-1-hybrid screen could be 
performed to identify transcription factors that bind to the G2 cyclin promoter regions; 
cross-referencing with the microarray data.  
As well as elucidating Ras function, the identification of Protein X would provide an 
important target for drug discovery.  
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